Keywords
Last Name
Institution

David P Nicolau PharmD, FCCP, FIDSA

TitleDirector
InstitutionHartford Hospital
DepartmentCenter for Anti-Infective Research and Development
Address80 Seymour Street
Phone860-545-3941
Fax860-545-3992
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Grupper M, Kuti JL, Nicolau DP. Continuous and Prolonged Intravenous ß-Lactam Dosing: Implications for the Clinical Laboratory. Clin Microbiol Rev. 2016 Oct; 29(4):759-72. PMID: 27413094.
      View in: PubMed
    2. Sartelli M, Weber DG, Ruppé E, Bassetti M, Wright BJ, Ansaloni L, Catena F, Coccolini F, Abu-Zidan FM, Coimbra R, Moore EE, Moore FA, Maier RV, De Waele JJ, Kirkpatrick AW, Griffiths EA, Eckmann C, Brink AJ, Mazuski JE, May AK, Sawyer RG, Mertz D, Montravers P, Kumar A, Roberts JA, Vincent JL, Watkins RR, Lowman W, Spellberg B, Abbott IJ, Adesunkanmi AK, Al-Dahir S, Al-Hasan MN, Agresta F, Althani AA, Ansari S, Ansumana R, Augustin G, Bala M, Balogh ZJ, Baraket O, Bhangu A, Beltrán MA, Bernhard M, Biffl WL, Boermeester MA, Brecher SM, Cherry-Bukowiec JR, Buyne OR, Cainzos MA, Cairns KA, Camacho-Ortiz A, Chandy SJ, Che Jusoh A, Chichom-Mefire A, Colijn C, Corcione F, Cui Y, Curcio D, Delibegovic S, Demetrashvili Z, De Simone B, Dhingra S, Diaz JJ, Di Carlo I, Dillip A, Di Saverio S, Doyle MP, Dorj G, Dogjani A, Dupont H, Eachempati SR, Enani MA, Egiev VN, Elmangory MM, Ferrada P, Fitchett JR, Fraga GP, Guessennd N, Giamarellou H, Ghnnam W, Gkiokas G, Goldberg SR, Gomes CA, Gomi H, Guzmán-Blanco M, Haque M, Hansen S, Hecker A, Heizmann WR, Herzog T, Hodonou AM, Hong SK, Kafka-Ritsch R, Kaplan LJ, Kapoor G, Karamarkovic A, Kees MG, Kenig J, Kiguba R, Kim PK, Kluger Y, Khokha V, Koike K, Kok KY, Kong V, Knox MC, Inaba K, Isik A, Iskandar K, Ivatury RR, Labbate M, Labricciosa FM, Laterre PF, Latifi R, Lee JG, Lee YR, Leone M, Leppaniemi A, Li Y, Liang SY, Loho T, Maegele M, Malama S, Marei HE, Martin-Loeches I, Marwah S, Massele A, McFarlane M, Melo RB, Negoi I, Nicolau DP, Nord CE, Ofori-Asenso R, Omari AH, Ordonez CA, Ouadii M, Pereira Júnior GA, Piazza D, Pupelis G, Rawson TM, Rems M, Rizoli S, Rocha C, Sakakhushev B, Sanchez-Garcia M, Sato N, Segovia Lohse HA, Sganga G, Siribumrungwong B, Shelat VG, Soreide K, Soto R, Talving P, Tilsed JV, Timsit JF, Trueba G, Trung NT, Ulrych J, van Goor H, Vereczkei A, Vohra RS, Wani I, Uhl W, Xiao Y, Yuan KC, Zachariah SK, Zahar JR, Zakrison TL, Corcione A, Melotti RM, Viscoli C, Viale P. Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA). World J Emerg Surg. 2016; 11:33. PMID: 27429642.
      View in: PubMed
    3. Kuti JL, Nicolau DP. Stability of Ertapenem 100 mg/mL at Room Temperature. Can J Hosp Pharm. 2016 May-Jun; 69(3):256-9. PMID: 27403009.
      View in: PubMed
    4. Thabit AK, Nicolau DP. An exploratory study to evaluate Clostridium difficile polymerase chain reaction ribotypes and infection outcomes. Infect Drug Resist. 2016; 9:143-8. PMID: 27390531.
      View in: PubMed
    5. Sutherland CA, Verastegui JE, Nicolau DP. In vitro potency of amikacin and comparators against E. coli, K. pneumoniae and P. aeruginosa respiratory and blood isolates. Ann Clin Microbiol Antimicrob. 2016; 15(1):39. PMID: 27316973.
      View in: PubMed
    6. Ghazi IM, Crandon JL, Lesho EP, McGann P, Nicolau DP. In vivo efficacy of humanized high dose meropenem and comparators against Pseudomonas aeruginosa isolates producing verona integron-encoded metallo-ß-lactamase (VIM). Heliyon. 2016 Jun; 2(6):e00121. PMID: 27441293.
      View in: PubMed
    7. Verastegui JE, Hamada Y, Nicolau DP. Transitions of care in the management of acute bacterial skin and skin structure infections: a paradigm shift. Expert Rev Clin Pharmacol. 2016 Aug; 9(8):1039-45. PMID: 27248789.
      View in: PubMed
    8. Nicolau DP, Dimopoulos G, Welte T, Luyt CE. Can we improve clinical outcomes in patients with pneumonia treated with antibiotics in the intensive care unit? Expert Rev Respir Med. 2016 Aug; 10(8):907-18. PMID: 27181707.
      View in: PubMed
    9. Jensen IS, Wu E, Fan W, Lodise TP, Nicolau DP, Dufour S, Cyr PL, Sulham KA. Use of Oritavancin in Moderate-to-Severe ABSSSI Patients Requiring IV Antibiotics: A U.S. Payer Budget Impact Analysis. J Manag Care Spec Pharm. 2016 Jun; 22(6):752-64. PMID: 27231802.
      View in: PubMed
    10. Zmarlicka MT, Cardwell SM, Crandon JL, Nicolau DP, McClure MH, Nailor MD. Evaluation of a disease state management guideline for urinary tract infection. Int J Antimicrob Agents. 2016 Jun; 47(6):451-6. PMID: 27211208.
      View in: PubMed
    11. Bassetti M, Luyt CE, Nicolau DP, Pugin J. Characteristics of an ideal nebulized antibiotic for the treatment of pneumonia in the intubated patient. Ann Intensive Care. 2016 Dec; 6(1):35. PMID: 27090532.
      View in: PubMed
    12. Thabit AK, Alam MJ, Khaleduzzaman M, Garey KW, Nicolau DP. A pilot study to assess bacterial and toxin reduction in patients with Clostridium difficile infection given fidaxomicin or vancomycin. Ann Clin Microbiol Antimicrob. 2016; 15(1):22. PMID: 27071986.
      View in: PubMed
    13. Sutherland CA, Nicolau DP. Development of an HPLC Method for the Determination of Ceftolozane/Tazobactam in Biological and Aqueous Matrixes. J Chromatogr Sci. 2016 Jul; 54(6):1037-40. PMID: 27048639.
      View in: PubMed
    14. Koomanachai P, Yungyuen T, Disthaporn P, Kiratisin P, Nicolau DP. Application of Pharmacodynamic Profiling for the Selection of Optimal ß-lactam Regimens in a Large University Hospital. Int J Infect Dis. 2016 May; 46:22-6. PMID: 27021531.
      View in: PubMed
    15. Patel UC, Nicolau DP, Sabzwari RK. Successful Treatment of Multi-Drug Resistant Pseudomonas aeruginosa Bacteremia with the Recommended Renally Adjusted Ceftolozane/Tazobactam Regimen. Infect Dis Ther. 2016 Mar; 5(1):73-9. PMID: 26935574.
      View in: PubMed
    16. Linder KE, Nicolau DP, Nailor MD. Predicting and preventing antimicrobial resistance utilizing pharmacodynamics: Part I gram positive bacteria. Expert Opin Drug Metab Toxicol. 2016 Mar; 12(3):267-80. PMID: 26751348.
      View in: PubMed
    17. Ghazi IM, Nicolau DP, Nailor MD, Aslanzadeh J, Ross JW, Kuti JL. Antibiotic Utilization and Opportunities for Stewardship Among Hospitalized Patients With Influenza Respiratory Tract Infection. Infect Control Hosp Epidemiol. 2016 May; 37(5):583-9. PMID: 26832841.
      View in: PubMed
    18. Jensen IS, Lodise TP, Fan W, Wu C, Cyr PL, Nicolau DP, DuFour S, Sulham KA. Use of Oritavancin in Acute Bacterial Skin and Skin Structure Infections Patients Receiving Intravenous Antibiotics: A US Hospital Budget Impact Analysis. Clin Drug Investig. 2016 Feb; 36(2):157-68. PMID: 26692006.
      View in: PubMed
    19. So W, Kuti JL, Shepard A, Nugent J, Nicolau DP. Tissue penetration and exposure of cefepime in patients with diabetic foot infections. Int J Antimicrob Agents. 2016 Mar; 47(3):247-8. PMID: 26897754.
      View in: PubMed
    20. Monogue ML, Kuti JL, Nicolau DP. Optimizing Antibiotic Dosing Strategies for the Treatment of Gram-negative Infections in the Era of Resistance. Expert Rev Clin Pharmacol. 2016 Mar; 9(3):459-76. PMID: 26678036.
      View in: PubMed
    21. Cardwell SM, Crandon JL, Nicolau DP, McClure MH, Nailor MD. Epidemiology and economics of adult patients hospitalized with urinary tract infections. Hosp Pract (1995). 2016 Feb; 44(1):33-40. PMID: 26673518.
      View in: PubMed
    22. Balwan A, Nicolau DP, Wungwattana M, Zuckerman JB, Waters V. Clinafloxacin for Treatment of Burkholderia cenocepacia Infection in a Cystic Fibrosis Patient. Antimicrob Agents Chemother. 2016 Jan; 60(1):1-5. PMID: 26722110.
      View in: PubMed
    23. Oliver WD, Heil EL, Gonzales JP, Mehrotra S, Robinett K, Saleeb P, Nicolau DP. Ceftolozane-Tazobactam Pharmacokinetics in a Critically Ill Patient on Continuous Venovenous Hemofiltration. Antimicrob Agents Chemother. 2015; 60(3):1899-901. PMID: 26711770.
      View in: PubMed
    24. Rhodes NJ, Kuti JL, Nicolau DP, Neely MN, Nicasio AM, Scheetz MH. An exploratory analysis of the ability of a cefepime trough concentration greater than 22 mg/L to predict neurotoxicity. J Infect Chemother. 2016 Feb; 22(2):78-83. PMID: 26712584.
      View in: PubMed
    25. Rhodes NJ, Kuti JL, Nicolau DP, Van Wart S, Nicasio AM, Liu J, Lee BJ, Neely MN, Scheetz MH. Defining Clinical Exposures of Cefepime for Gram-Negative Bloodstream Infections That Are Associated with Improved Survival. Antimicrob Agents Chemother. 2015; 60(3):1401-10. PMID: 26666929.
      View in: PubMed
    26. Hamada Y, Kuti JL, Nicolau DP. In Vitro Pharmacodynamics of Vancomycin against Methicillin-Susceptible and -Resistant Staphylococcus aureus: Considering the Variability in Observed Tissue Exposure. Antimicrob Agents Chemother. 2015; 60(2):955-61. PMID: 26621619.
      View in: PubMed
    27. Housman ST, Thabit AK, Kuti JL, Quintiliani R, Nicolau DP. Assessment of Clostridium difficile Burden in Patients Over Time With First Episode Infection Following Fidaxomicin or Vancomycin. Infect Control Hosp Epidemiol. 2016 Feb; 37(2):215-8. PMID: 26592763.
      View in: PubMed
    28. So W, Crandon JL, Hamada Y, Nicolau DP. Antibacterial activity of achievable epithelial lining fluid exposures of Amikacin Inhale with or without meropenem. J Antimicrob Chemother. 2016 Feb; 71(2):428-37. PMID: 26559690.
      View in: PubMed
    29. So W, Crandon JL, Nicolau DP. Poor outcomes of empiric ceftriaxone ± azithromycin for community-acquired pneumonia caused by methicillin-susceptible Staphylococcus aureus. Intern Emerg Med. 2016 Jun; 11(4):545-51. PMID: 26531307.
      View in: PubMed
    30. Magsarili HK, Girotto JE, Bennett NJ, Nicolau DP. Making a Case for Pediatric Antimicrobial Stewardship Programs. Pharmacotherapy. 2015 Nov; 35(11):1026-36. PMID: 26598095.
      View in: PubMed
    31. Ray A, Malin D, Nicolau DP, Wiskirchen DE. Antibiotic Tissue Penetration in Diabetic Foot Infections A Review of the Microdialysis Literature and Needs for Future Research. J Am Podiatr Med Assoc. 2015 Nov; 105(6):520-31. PMID: 26667505.
      View in: PubMed
    32. Thabit AK, Nicolau DP, Kuti JL. In Vitro Pharmacodynamics of Human Simulated Exposures of Telavancin against Methicillin-Susceptible and -Resistant Staphylococcus aureus with and without Prior Vancomycin Exposure. Antimicrob Agents Chemother. 2015; 60(1):222-8. PMID: 26482306.
      View in: PubMed
    33. Kim A, Kutschke A, Ehmann DE, Patey SA, Crandon JL, Gorseth E, Miller AA, McLaughlin RE, Blinn CM, Chen A, Nayar AS, Dangel B, Tsai AS, Rooney MT, Murphy-Benenato KE, Eakin AE, Nicolau DP. Pharmacodynamic Profiling of a Siderophore-Conjugated Monocarbam in Pseudomonas aeruginosa: Assessing the Risk for Resistance and Attenuated Efficacy. Antimicrob Agents Chemother. 2015 Dec; 59(12):7743-52. PMID: 26438502.
      View in: PubMed
    34. Furtado GH, Cardinal L, Macedo RS, Silva JO, Medeiros EA, Kuti JL, Nicolau DP. Pharmacokinetic/pharmacodynamic target attainment of intravenous ß-lactam regimens against Gram-negative bacteria isolated in a Brazilian teaching hospital. Rev Soc Bras Med Trop. 2015 Oct; 48(5):539-45. PMID: 26516962.
      View in: PubMed
    35. Ghazi IM, Crandon JL, Lesho EP, McGann P, Nicolau DP. Efficacy of Humanized High-Dose Meropenem, Cefepime, and Levofloxacin against Enterobacteriaceae Isolates Producing Verona Integron-Encoded Metallo-ß-Lactamase (VIM) in a Murine Thigh Infection Model. Antimicrob Agents Chemother. 2015 Nov; 59(11):7145-7. PMID: 26416855; PMCID: PMC4604359 [Available on 05/01/16].
    36. Pettit RS, Neu N, Cies JJ, Lapin C, Muhlebach MS, Novak KJ, Nguyen ST, Saiman L, Nicolau DP, Kuti JL. Population pharmacokinetics of meropenem administered as a prolonged infusion in children with cystic fibrosis. J Antimicrob Chemother. 2016 Jan; 71(1):189-95. PMID: 26416780.
      View in: PubMed
    37. Sharareh B, Sutherland C, Pourmand D, Molina N, Nicolau DP, Schwarzkopf R. Effect of Body Weight on Cefazolin and Vancomycin Trabecular Bone Concentrations in Patients Undergoing Total Joint Arthroplasty. Surg Infect (Larchmt). 2016 Jan; 17(1):71-7. PMID: 26397726.
      View in: PubMed
    38. Housman ST, Bhalodi AA, Shepard A, Nugent J, Nicolau DP. Vancomycin Tissue Pharmacokinetics in Patients with Lower-Limb Infections via In Vivo Microdialysis. J Am Podiatr Med Assoc. 2015 Sep; 105(5):381-8. PMID: 26429605.
      View in: PubMed
    39. Xiao AJ, Miller BW, Huntington JA, Nicolau DP. Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia. J Clin Pharmacol. 2016 Jan; 56(1):56-66. PMID: 26096377.
      View in: PubMed
    40. Zmarlicka MT, Nailor MD, Nicolau DP. Impact of the New Delhi metallo-beta-lactamase on beta-lactam antibiotics. Infect Drug Resist. 2015; 8:297-309. PMID: 26345624; PMCID: PMC4554481.
    41. Hollis AL, Heil EL, Nicolau DP, Odonkor P, Dowling TC, Thom KA. Validation of a Dosing Strategy for Cefazolin for Surgery Requiring Cardiopulmonary Bypass. Surg Infect (Larchmt). 2015 Dec; 16(6):829-32. PMID: 26291478.
      View in: PubMed
    42. Crandon JL, Nicolau DP. In Vitro Activity of Cefepime/AAI101 and Comparators against Cefepime Non-susceptible Enterobacteriaceae. Pathogens. 2015; 4(3):620-5. PMID: 26295262; PMCID: PMC4584277.
    43. Kang N, Housman ST, Nicolau DP. Assessing the Surrogate Susceptibility of Oxacillin and Cefoxitin for Commonly Utilized Parenteral Agents against Methicillin-Susceptible Staphylococcus aureus: Focus on Ceftriaxone Discordance between Predictive Susceptibility and in Vivo Exposures. Pathogens. 2015; 4(3):599-605. PMID: 26264030; PMCID: PMC4584275.
    44. Nicolau DP. Focus on ceftazidime-avibactam for optimizing outcomes in complicated intra-abdominal and urinary tract infections. Expert Opin Investig Drugs. 2015; 24(9):1261-73. PMID: 26145447.
      View in: PubMed
    45. Nicolau DP, Siew L, Armstrong J, Li J, Edeki T, Learoyd M, Das S. Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens. J Antimicrob Chemother. 2015 Oct; 70(10):2862-9. PMID: 26133566.
      View in: PubMed
    46. Housman ST, Banevicius MA, Lamb LM, Nicolau DP. Isolation and quantitation of Clostridium difficile in aqueous and fecal matter using two types of selective media. J Microbiol Immunol Infect. 2016 Jun; 49(3):445-7. PMID: 26198865.
      View in: PubMed
    47. O'Dowd H, Shannon DE, Chandupatla KR, Dixit V, Engtrakul JJ, Ye Z, Jones SM, O'Brien CF, Nicolau DP, Tessier PR, Crandon JL, Song B, Macikenas D, Hanzelka BL, Le Tiran A, Bennani YL, Charifson PS, Grillot AL. Discovery and Characterization of a Water-Soluble Prodrug of a Dual Inhibitor of Bacterial DNA Gyrase and Topoisomerase IV. ACS Med Chem Lett. 2015 Jul 9; 6(7):822-6. PMID: 26191374; PMCID: PMC4499827 [Available on 07/09/16].
    48. Sutherland CA, Nicolau DP. Susceptibility Profile of Ceftolozane/Tazobactam and Other Parenteral Antimicrobials Against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa From US Hospitals. Clin Ther. 2015 Jul 1; 37(7):1564-71. PMID: 26088525.
      View in: PubMed
    49. So W, Crandon JL, Nicolau DP. Pharmacodynamic Profile of GSK2140944 against Methicillin-Resistant Staphylococcus aureus in a Murine Lung Infection Model. Antimicrob Agents Chemother. 2015 Aug; 59(8):4956-61. PMID: 26055376; PMCID: PMC4505212 [Available on 02/01/16].
    50. Thabit AK, Nicolau DP. Impact of vancomycin faecal concentrations on clinical and microbiological outcomes in Clostridium difficile infection. Int J Antimicrob Agents. 2015 Aug; 46(2):205-8. PMID: 26055927.
      View in: PubMed
    51. Swank ML, Wing DA, Nicolau DP, McNulty JA. Increased 3-gram cefazolin dosing for cesarean delivery prophylaxis in obese women. Am J Obstet Gynecol. 2015 Sep; 213(3):415.e1-8. PMID: 26003059.
      View in: PubMed
    52. Maggio L, Nicolau DP, DaCosta M, Rouse DJ, Hughes BL. Cefazolin prophylaxis in obese women undergoing cesarean delivery: a randomized controlled trial. Obstet Gynecol. 2015 May; 125(5):1205-10. PMID: 25932849.
      View in: PubMed
    53. Kuti JL, Pettit RS, Neu N, Cies JJ, Lapin C, Muhlebach MS, Novak KJ, Nguyen ST, Saiman L, Nicolau DP. Microbiological activity of ceftolozane/tazobactam, ceftazidime, meropenem, and piperacillin/tazobactam against Pseudomonas aeruginosa isolated from children with cystic fibrosis. Diagn Microbiol Infect Dis. 2015 Sep; 83(1):53-5. PMID: 26003469.
      View in: PubMed
    54. Hamada Y, Kuti JL, Nicolau DP. Vancomycin serum concentrations do not adequately predict tissue exposure in diabetic patients with mild to moderate limb infections. J Antimicrob Chemother. 2015 Jul; 70(7):2064-7. PMID: 25802284.
      View in: PubMed
    55. Bassetti M, De Waele JJ, Eggimann P, Garnacho-Montero J, Kahlmeter G, Menichetti F, Nicolau DP, Paiva JA, Tumbarello M, Welte T, Wilcox M, Zahar JR, Poulakou G. Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria. Intensive Care Med. 2015 May; 41(5):776-95. PMID: 25792203.
      View in: PubMed
    56. Thabit AK, Nicolau DP. Lack of Correlation between Bristol Stool Scale and Quantitative Bacterial Load in Clostridium difficile Infection. Infect Dis (Auckl). 2015; 8:1-4. PMID: 25780339; PMCID: PMC4346303.
    57. Crandon JL, Nicolau DP. In vivo activities of simulated human doses of cefepime and cefepime-AAI101 against multidrug-resistant Gram-negative Enterobacteriaceae. Antimicrob Agents Chemother. 2015 May; 59(5):2688-94. PMID: 25712356; PMCID: PMC4394792.
    58. Hamada Y, Sutherland CA, Nicolau DP. Impact of revised cefepime CLSI breakpoints on Escherichia coli and Klebsiella pneumoniae susceptibility and potential impact if applied to Pseudomonas aeruginosa. J Clin Microbiol. 2015 May; 53(5):1712-4. PMID: 25694527; PMCID: PMC4400738.
    59. Kuti JL, Nicolau DP. Presence of infection influences the epithelial lining fluid penetration of oral levofloxacin in adult patients. Int J Antimicrob Agents. 2015 May; 45(5):512-8. PMID: 25726443.
      View in: PubMed
    60. So W, Crandon JL, Nicolau DP. Effects of Urine Matrix and pH on the Potency of Delafloxacin and Ciprofloxacin against Urogenic Escherichia coli and Klebsiella pneumoniae. J Urol. 2015 Aug; 194(2):563-70. PMID: 25637857.
      View in: PubMed
    61. Tomaras AP, Crandon JL, McPherson CJ, Nicolau DP. Potentiation of antibacterial activity of the MB-1 siderophore-monobactam conjugate using an efflux pump inhibitor. Antimicrob Agents Chemother. 2015 Apr; 59(4):2439-42. PMID: 25605364; PMCID: PMC4356814.
    62. Heil EL, Lowery AV, Thom KA, Nicolau DP. Treatment of multidrug-resistant pseudomonas aeruginosa using extended-infusion antimicrobial regimens. Pharmacotherapy. 2015 Jan; 35(1):54-8. PMID: 25556715.
      View in: PubMed
    63. Thabit AK, Crandon JL, Nicolau DP. Antimicrobial resistance: impact on clinical and economic outcomes and the need for new antimicrobials. Expert Opin Pharmacother. 2015 Feb; 16(2):159-77. PMID: 25496207.
      View in: PubMed
    64. So W, Kuti JL, Nicolau DP. Population Pharmacokinetics of Cefazolin in Serum and Tissue for Patients with Complicated Skin and Soft Tissue Infections (cSSTI). Infect Dis Ther. 2014 Dec; 3(2):269-79. PMID: 25410773.
      View in: PubMed
    65. MacVane SH, So W, Nicolau DP, Kuti JL. In vitro activity of human-simulated epithelial lining fluid exposures of ceftaroline, ceftriaxone, and vancomycin against methicillin-susceptible and -resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2014 Dec; 58(12):7520-6. PMID: 25288076; PMCID: PMC4249498.
    66. Blanchette LM, Kuti JL, Nicolau DP, Nailor MD. Clinical comparison of ertapenem and cefepime for treatment of infections caused by AmpC beta-lactamase-producing Enterobacteriaceae. Scand J Infect Dis. 2014 Nov; 46(11):803-8. PMID: 25262922.
      View in: PubMed
    67. Bhalodi AA, Crandon JL, Williams G, Nicolau DP. Supporting the ceftaroline fosamil/avibactam Enterobacteriaceae breakpoint determination using humanised in vivo exposures in a thigh model. Int J Antimicrob Agents. 2014 Dec; 44(6):508-13. PMID: 25278330.
      View in: PubMed
    68. MacVane SH, Crandon JL, Nichols WW, Nicolau DP. In vivo efficacy of humanized exposures of Ceftazidime-Avibactam in comparison with Ceftazidime against contemporary Enterobacteriaceae isolates. Antimicrob Agents Chemother. 2014 Nov; 58(11):6913-9. PMID: 25223999; PMCID: PMC4249385.
    69. MacVane SH, Crandon JL, Nichols WW, Nicolau DP. Unexpected in vivo activity of ceftazidime alone and in combination with avibactam against New Delhi metallo-ß-lactamase-producing Enterobacteriaceae in a murine thigh infection model. Antimicrob Agents Chemother. 2014 Nov; 58(11):7007-9. PMID: 25223998; PMCID: PMC4249434.
    70. Sutherland CA, Nicolau DP. To add or not to add polysorbate 80: impact on colistin MICs for clinical strains of Enterobacteriaceae and Pseudomonas aeruginosa and quality controls. J Clin Microbiol. 2014 Oct; 52(10):3810. PMID: 25210064; PMCID: PMC4187774.
    71. Jain JG, Sutherland C, Nicolau DP, Kuti JL. Stability of ertapenem 100 mg/mL in polypropylene syringes stored at 25, 4, and -20 °C. Am J Health Syst Pharm. 2014 Sep 1; 71(17):1480-4. PMID: 25147172.
      View in: PubMed
    72. So W, Crandon JL, Zhanel GG, Nicolau DP. Comparison of in vivo and in vitro pharmacodynamics of a humanized regimen of 600 milligrams of Ceftaroline Fosamil every 12 hours against Staphylococcus aureus at initial inocula of 106 and 108 CFU per milliliter. Antimicrob Agents Chemother. 2014 Nov; 58(11):6931-3. PMID: 25136006; PMCID: PMC4249378.
    73. Housman ST, Sutherland CA, Nicolau DP. Pharmacodynamic profile of commonly utilised parenteral therapies against meticillin-susceptible and meticillin-resistant Staphylococcus aureus collected from US hospitals. Int J Antimicrob Agents. 2014 Sep; 44(3):235-41. PMID: 25052866.
      View in: PubMed
    74. MacVane SH, Housman ST, Nicolau DP. In vitro microdialysis membrane efficiency of broad-spectrum antibiotics in combination and alone. Clin Pharmacol. 2014; 6:97-101. PMID: 24940084; PMCID: PMC4051625.
    75. MacVane SH, Tuttle LO, Nicolau DP. Demography and burden of care associated with patients readmitted for urinary tract infection. J Microbiol Immunol Infect. 2015 Oct; 48(5):517-24. PMID: 24863498.
      View in: PubMed
    76. Jain JG, Housman ST, Nicolau DP. Humanized tissue pharmacodynamics of cefazolin against commonly isolated pathogens in skin and skin structure infections. J Antimicrob Chemother. 2014 Sep; 69(9):2443-7. PMID: 24827890.
      View in: PubMed
    77. Perola E, Stamos D, Grillot AL, Ronkin S, Wang T, LeTiran A, Tang Q, Deininger DD, Liao Y, Tian SK, Drumm JE, Nicolau DP, Tessier PR, Mani N, Grossman TH, Charifson PS. Successful application of serum shift prediction models to the design of dual targeting inhibitors of bacterial gyrase B and topoisomerase IV with improved in vivo efficacy. Bioorg Med Chem Lett. 2014 May 1; 24(9):2177-81. PMID: 24685546.
      View in: PubMed
    78. Maglio D, Sun HK, Patel T, Banevicius MA, Nightingale CH, Arya A, Wang G, Chen Z, Phan LT, Nicolau DP. Pharmacodynamic profiling of modithromycin: assessment in a pneumococcal murine pneumonia model. Int J Antimicrob Agents. 2014 Jun; 43(6):540-6. PMID: 24703590.
      View in: PubMed
    79. Connors KP, Housman ST, Pope JS, Russomanno J, Salerno E, Shore E, Redican S, Nicolau DP. Phase I, open-label, safety and pharmacokinetic study to assess bronchopulmonary disposition of intravenous eravacycline in healthy men and women. Antimicrob Agents Chemother. 2014; 58(4):2113-8. PMID: 24468780; PMCID: PMC4023791.
    80. MacVane SH, Tuttle LO, Nicolau DP. Impact of extended-spectrum ß-lactamase-producing organisms on clinical and economic outcomes in patients with urinary tract infection. J Hosp Med. 2014 Apr; 9(4):232-8. PMID: 24464783.
      View in: PubMed
    81. Wiskirchen DE, Nordmann P, Crandon JL, Nicolau DP. In vivo efficacy of human simulated regimens of carbapenems and comparator agents against NDM-1-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2014; 58(3):1671-7. PMID: 24379195; PMCID: PMC3957895.
    82. Wiskirchen DE, Nordmann P, Crandon JL, Nicolau DP. Efficacy of humanized carbapenem and ceftazidime regimens against Enterobacteriaceae producing OXA-48 carbapenemase in a murine infection model. Antimicrob Agents Chemother. 2014; 58(3):1678-83. PMID: 24379200; PMCID: PMC3957853.
    83. Bassetti M, Nicolau DP, Calandra T. What's new in antimicrobial use and resistance in critically ill patients? Intensive Care Med. 2014 Mar; 40(3):422-6. PMID: 24346656.
      View in: PubMed
    84. Housman ST, Crandon JL, Nichols WW, Nicolau DP. Efficacies of ceftazidime-avibactam and ceftazidime against Pseudomonas aeruginosa in a murine lung infection model. Antimicrob Agents Chemother. 2014; 58(3):1365-71. PMID: 24342641; PMCID: PMC3957844.
    85. MacVane SH, Kuti JL, Nicolau DP. Clinical pharmacodynamics of antipseudomonal cephalosporins in patients with ventilator-associated pneumonia. Antimicrob Agents Chemother. 2014; 58(3):1359-64. PMID: 24342637; PMCID: PMC3957877.
    86. Perez F, Arias CA, Bush K, Drusano GL, Lolans K, Munoz-Price LS, Nicolau DP, Queenan AM, Rice LB, Segreti J, Shlaes DM, Weinstein RA, Bonomo RA. In memoriam: John P. Quinn, MD. Clin Infect Dis. 2014 Mar; 58(5):748-50. PMID: 24336826; PMCID: PMC3934997.
    87. Hagihara M, Housman ST, Nicolau DP, Kuti JL. In vitro pharmacodynamics of polymyxin B and tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2014; 58(2):874-9. PMID: 24277022; PMCID: PMC3910875.
    88. MacVane SH, Kuti JL, Nicolau DP. Prolonging ß-lactam infusion: a review of the rationale and evidence, and guidance for implementation. Int J Antimicrob Agents. 2014 Feb; 43(2):105-13. PMID: 24359838.
      View in: PubMed
    89. Bhalodi AA, Hagihara M, Nicolau DP, Kuti JL. In vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposure. Antimicrob Agents Chemother. 2014; 58(2):672-7. PMID: 24217694; PMCID: PMC3910832.
    90. Macvane SH, Crandon JL, Nicolau DP. Characterizing in vivo pharmacodynamics of carbapenems against Acinetobacter baumannii in a murine thigh infection model to support breakpoint determinations. Antimicrob Agents Chemother. 2014; 58(1):599-601. PMID: 24165174; PMCID: PMC3910748.
    91. Beaulac KR, Nailor MD, Nicolau DP, Kuti JL. The authors reply. Crit Care Med. 2013 Oct; 41(10):e298. PMID: 24060802.
      View in: PubMed
    92. Bhalodi AA, Crandon JL, Williams G, Nicolau DP. In vivo efficacy of humanized ceftaroline fosamil-avibactam exposures in a polymicrobial infection model. Antimicrob Agents Chemother. 2013 Nov; 57(11):5674-8. PMID: 24041891; PMCID: PMC3811285.
    93. Bhalodi AA, Housman ST, Shepard A, Nugent J, Nicolau DP. Tissue pharmacokinetics of cefazolin in patients with lower limb infections. Antimicrob Agents Chemother. 2013 Nov; 57(11):5679-83. PMID: 24041887; PMCID: PMC3811311.
    94. Raman K, Nailor MD, Nicolau DP, Aslanzadeh J, Nadeau M, Kuti JL. Early antibiotic discontinuation in patients with clinically suspected ventilator-associated pneumonia and negative quantitative bronchoscopy cultures. Crit Care Med. 2013 Jul; 41(7):1656-63. PMID: 23528805.
      View in: PubMed
    95. Crandon JL, MacVane SH, Nicolau DP. Clinical laboratory-based assay methodologies may underestimate and increase variability of vancomycin protein binding in hospitalized patients. Pharmacotherapy. 2014 Feb; 34(2):203-9. PMID: 23798336.
      View in: PubMed
    96. Magee TV, Brown MF, Starr JT, Ackley DC, Abramite JA, Aubrecht J, Butler A, Crandon JL, Dib-Hajj F, Flanagan ME, Granskog K, Hardink JR, Huband MD, Irvine R, Kuhn M, Leach KL, Li B, Lin J, Luke DR, MacVane SH, Miller AA, McCurdy S, McKim JM, Nicolau DP, Nguyen TT, Noe MC, O'Donnell JP, Seibel SB, Shen Y, Stepan AF, Tomaras AP, Wilga PC, Zhang L, Xu J, Chen JM. Discovery of Dap-3 polymyxin analogues for the treatment of multidrug-resistant Gram-negative nosocomial infections. J Med Chem. 2013 Jun 27; 56(12):5079-93. PMID: 23735048.
      View in: PubMed
    97. Tomaras AP, Crandon JL, McPherson CJ, Banevicius MA, Finegan SM, Irvine RL, Brown MF, O'Donnell JP, Nicolau DP. Adaptation-based resistance to siderophore-conjugated antibacterial agents by Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2013 Sep; 57(9):4197-207. PMID: 23774440; PMCID: PMC3754284.
    98. Wiskirchen DE, Nordmann P, Crandon JL, Nicolau DP. Efficacy of humanized carbapenem exposures against New Delhi metallo-ß-lactamase (NDM-1)-producing enterobacteriaceae in a murine infection model. Antimicrob Agents Chemother. 2013 Aug; 57(8):3936-40. PMID: 23733463; PMCID: PMC3719754.
    99. Goff DA, Nicolau DP. When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents. Clin Ther. 2013 Jun; 35(6):766-71. PMID: 23795574.
      View in: PubMed
    100. Housman ST, Hagihara M, Nicolau DP, Kuti JL. In vitro pharmacodynamics of human-simulated exposures of ampicillin/sulbactam, doripenem and tigecycline alone and in combination against multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother. 2013 Oct; 68(10):2296-304. PMID: 23710070.
      View in: PubMed
    101. Crandon JL, Nicolau DP. Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo-ß-lactamase producers. Antimicrob Agents Chemother. 2013 Jul; 57(7):3299-306. PMID: 23650162; PMCID: PMC3697389.
    102. Wiskirchen DE, Crandon JL, Nicolau DP. Impact of various conditions on the efficacy of dual carbapenem therapy against KPC-producing Klebsiella pneumoniae. Int J Antimicrob Agents. 2013 Jun; 41(6):582-5. PMID: 23611306.
      View in: PubMed
    103. Bhalodi AA, Keel RA, Quintiliani R, Lodise TP, Nicolau DP, Kuti JL. Pharmacokinetics of doripenem in infected patients treated within and outside the intensive care unit. Ann Pharmacother. 2013 May; 47(5):617-27. PMID: 23585647.
      View in: PubMed
    104. Tessier PR, Nicolau DP. In vitro activity of novel gyrase inhibitors against a highly resistant population of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2013 Jun; 57(6):2887-9. PMID: 23571537; PMCID: PMC3716190.
    105. Hagihara M, Crandon JL, Urban C, Nicolau DP. Efficacy of doripenem and ertapenem against KPC-2-producing and non-KPC-producing Klebsiella pneumoniae with similar MICs. J Antimicrob Chemother. 2013 Jul; 68(7):1616-8. PMID: 23475648.
      View in: PubMed
    106. Wiskirchen DE, Housman ST, Quintiliani R, Nicolau DP, Kuti JL. Comparative pharmacokinetics, pharmacodynamics, and tolerability of ertapenem 1 gram/day administered as a rapid 5-minute infusion versus the standard 30-minute infusion in healthy adult volunteers. Pharmacotherapy. 2013 Mar; 33(3):266-74. PMID: 23400916.
      View in: PubMed
    107. Banevicius MA, Kaplan N, Hafkin B, Nicolau DP. Pharmacokinetics, pharmacodynamics and efficacy of novel FabI inhibitor AFN-1252 against MSSA and MRSA in the murine thigh infection model. J Chemother. 2013 Feb; 25(1):26-31. PMID: 23433441; PMCID: PMC3558988.
    108. Lamb LM, Crandon JL, Nicolau DP. Pharmacokinetic and pharmacodynamic evaluation of P-873 versus Klebsiella pneumoniae in a neutropenic murine thigh infection model. Antimicrob Agents Chemother. 2013 Apr; 57(4):1971-3. PMID: 23357768; PMCID: PMC3623370.
    109. Hagihara M, Crandon JL, Urban CM, Nicolau DP. KPC presence in Pseudomonas aeruginosa has minimal impact on the in vivo efficacy of carbapenem therapy. Antimicrob Agents Chemother. 2013 Feb; 57(2):1086-8. PMID: 23254422; PMCID: PMC3553679.
    110. Bhalodi AA, Papasavas PK, Tishler DS, Nicolau DP, Kuti JL. Pharmacokinetics of intravenous linezolid in moderately to morbidly obese adults. Antimicrob Agents Chemother. 2013 Mar; 57(3):1144-9. PMID: 23254421; PMCID: PMC3591894.
    111. Zadroga R, Williams DN, Gottschall R, Hanson K, Nordberg V, Deike M, Kuskowski M, Carlson L, Nicolau DP, Sutherland C, Hansen GT. Comparison of 2 blood culture media shows significant differences in bacterial recovery for patients on antimicrobial therapy. Clin Infect Dis. 2013 Mar; 56(6):790-7. PMID: 23223586.
      View in: PubMed
    112. Afaneh CI, Ho VP, McWhorter P, Nicolau DP, Barie PS. Minor fluctuations in renal function may alter therapeutic drug concentrations substantially during high-dose, continuous-infusion beta-lactam therapy for multi-drug-resistant Gram-negative bacilli. Surg Infect (Larchmt). 2012 Dec; 13(6):415-7. PMID: 23268616.
      View in: PubMed
    113. Kiratisin P, Keel RA, Nicolau DP. Pharmacodynamic profiling of doripenem, imipenem and meropenem against prevalent Gram-negative organisms in the Asia-Pacific region. Int J Antimicrob Agents. 2013 Jan; 41(1):47-51. PMID: 23127484.
      View in: PubMed
    114. Tessier PR, Nicolau DP. Tigecycline displays in vivo bactericidal activity against extended-spectrum-ß-lactamase-producing Enterobacteriaceae after 72-hour exposure period. Antimicrob Agents Chemother. 2013 Jan; 57(1):640-2. PMID: 23114764; PMCID: PMC3535914.
    115. Stein GE, Kulhanek G, Smith CL, Kuti JL, Nicolau DP, Scharmen A, Farnum C, Tran M, Kalra A, Havlichek DH. Pharmacokinetics and monte carlo simulations of doripenem in patients with febrile neutropenia. Ann Pharmacother. 2012 Oct; 46(10):1281-6. PMID: 23012385.
      View in: PubMed
    116. Crandon JL, Schuck VJ, Banevicius MA, Beaudoin ME, Nichols WW, Tanudra MA, Nicolau DP. Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2012 Dec; 56(12):6137-46. PMID: 22985878; PMCID: PMC3497209.
    117. Bhalodi AA, Crandon JL, Biek D, Nicolau DP. Efficacy of ceftaroline fosamil in a staphylococcal murine pneumonia model. Antimicrob Agents Chemother. 2012 Dec; 56(12):6160-5. PMID: 22985880; PMCID: PMC3497181.
    118. Wilde AM, Nailor MD, Nicolau DP, Kuti JL. Inappropriate antibiotic use due to decreased compliance with a ventilator-associated pneumonia computerized clinical pathway: implications for continuing education and prospective feedback. Pharmacotherapy. 2012 Aug; 32(8):755-63. PMID: 23307523.
      View in: PubMed
    119. Hagihara M, Sutherland C, Nicolau DP. Development of HPLC methods for the determination of vancomycin in human plasma, mouse serum and bronchoalveolar lavage fluid. J Chromatogr Sci. 2013 Mar; 51(3):201-7. PMID: 22851425.
      View in: PubMed
    120. Eagye KJ, Banevicius MA, Nicolau DP. Pseudomonas aeruginosa is not just in the intensive care unit any more: implications for empirical therapy. Crit Care Med. 2012 Apr; 40(4):1329-32. PMID: 22425824.
      View in: PubMed
    121. Keel RA, Crandon JL, Nicolau DP. Pharmacokinetics and pulmonary disposition of tedizolid and linezolid in a murine pneumonia model under variable conditions. Antimicrob Agents Chemother. 2012 Jun; 56(6):3420-2. PMID: 22430966; PMCID: PMC3370766.
    122. Rich BS, Keel R, Ho VP, Turbendian H, Afaneh CI, Dakin GF, Pomp A, Nicolau DP, Barie PS. Cefepime dosing in the morbidly obese patient population. Obes Surg. 2012 Mar; 22(3):465-71. PMID: 22249886.
      View in: PubMed
    123. Tessier PR, Keel RA, Hagihara M, Crandon JL, Nicolau DP. Comparative in vivo efficacies of epithelial lining fluid exposures of tedizolid, linezolid, and vancomycin for methicillin-resistant Staphylococcus aureus in a mouse pneumonia model. Antimicrob Agents Chemother. 2012 May; 56(5):2342-6. PMID: 22354302; PMCID: PMC3346598.
    124. Hagihara M, Crandon JL, Nicolau DP. The efficacy and safety of antibiotic combination therapy for infections caused by Gram-positive and Gram-negative organisms. Expert Opin Drug Saf. 2012 Mar; 11(2):221-33. PMID: 22074343.
      View in: PubMed
    125. Housman ST, Keel RA, Crandon JL, Williams G, Nicolau DP. Efficacy of human simulated exposures of ceftaroline against phenotypically diverse Enterobacteriaceae isolates. Antimicrob Agents Chemother. 2012 May; 56(5):2576-80. PMID: 22330908; PMCID: PMC3346611.
    126. Housman ST, Pope JS, Russomanno J, Salerno E, Shore E, Kuti JL, Nicolau DP. Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers. Antimicrob Agents Chemother. 2012 May; 56(5):2627-34. PMID: 22330925; PMCID: PMC3346604.
    127. Ho VP, Nicolau DP, Dakin GF, Pomp A, Rich BS, Towe CW, Barie PS. Cefazolin dosing for surgical prophylaxis in morbidly obese patients. Surg Infect (Larchmt). 2012 Feb; 13(1):33-7. PMID: 22316145.
      View in: PubMed
    128. Hagihara M, Kuti JL, Nicolau DP. Predicting doripenem susceptibility based on meropenem and imipenem interpretation for Pseudomonas aeruginosa. Diagn Microbiol Infect Dis. 2012 Mar; 72(3):258-62. PMID: 22209563.
      View in: PubMed
    129. Housman ST, Sutherland C, Nicolau DP. In vitro evaluation of novel compounds against selected resistant Pseudomonas aeruginosa isolates. Antimicrob Agents Chemother. 2012 Mar; 56(3):1646-9. PMID: 22203592; PMCID: PMC3294881.
    130. Nicolau DP, Sutherland C, Winget D, Baughman RP. Bronchopulmonary pharmacokinetic and pharmacodynamic profiles of levofloxacin 750 mg once daily in adults undergoing treatment for acute exacerbation of chronic bronchitis. Pulm Pharmacol Ther. 2012 Feb; 25(1):94-8. PMID: 22210007.
      View in: PubMed
    131. Eagye KJ, Nicolau DP. Selection of prophylactic antimicrobial agent may affect incidence of infection in small bowel and colorectal surgery. Surg Infect (Larchmt). 2011 Dec; 12(6):451-7. PMID: 22142316.
      View in: PubMed
    132. Stein GE, Smith CL, Missavage A, Saunders JP, Nicolau DP, Battjes SM, Kepros JP. Tigecycline penetration into skin and soft tissue. Surg Infect (Larchmt). 2011 Dec; 12(6):465-7. PMID: 22136488.
      View in: PubMed
    133. Housman ST, Tessier PR, Nicolau DP, Kuti JL. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration. Am J Health Syst Pharm. 2011 Dec 1; 68(23):2265-70. PMID: 22095816.
      View in: PubMed
    134. Bulik CC, Tessier PR, Keel RA, Sutherland CA, Nicolau DP. In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms. Antimicrob Agents Chemother. 2012 Jan; 56(1):544-9. PMID: 22064538; PMCID: PMC3256089.
    135. Nicolau DP, Carmeli Y, Crank CW, Goff DA, Graber CJ, Lima AL, Goldstein EJ. Carbapenem stewardship: does ertapenem affect Pseudomonas susceptibility to other carbapenems? A review of the evidence. Int J Antimicrob Agents. 2012 Jan; 39(1):11-5. PMID: 22047702.
      View in: PubMed
    136. Heil EL, Daniels LM, Walko CM, Nicolau DP, Smith EA. Validation of doripenem dosing in patients with end-stage renal disease receiving hemodialysis. Ann Pharmacother. 2011 Nov; 45(11):1455-6. PMID: 22009996.
      View in: PubMed
    137. Wiskirchen DE, Kuti JL, Nicolau DP. Acute physiology and chronic health evaluation II score is a better predictor of mortality than IBMP-10 in patients with ventilator-associated pneumonia. Surg Infect (Larchmt). 2011 Oct; 12(5):385-90. PMID: 22004437.
      View in: PubMed
    138. Hagihara M, Wiskirchen DE, Kuti JL, Nicolau DP. In vitro pharmacodynamics of vancomycin and cefazolin alone and in combination against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2012 Jan; 56(1):202-7. PMID: 22006007; PMCID: PMC3256059.
    139. Keel RA, Kuti JL, Sahm DF, Nicolau DP. Pharmacodynamic evaluation of i.v. antimicrobials against Pseudomonas aeruginosa samples collected from U.S. hospitals. Am J Health Syst Pharm. 2011 Sep 1; 68(17):1619-25. PMID: 21856807.
      View in: PubMed
    140. Villegas MV, Briceno DF, Ruiz SJ, Furtado GH, Nicolau DP. Assessing the pharmacodynamic profile of intravenous antibiotics against prevalent Gram-negative organisms collected in Colombia. Braz J Infect Dis. 2011 Sep-Oct; 15(5):413-9. PMID: 22230846.
      View in: PubMed
    141. Ho VP, Jenkins SG, Afaneh CI, Turbendian HK, Nicolau DP, Barie PS. Use of meropenem by continuous infusion to treat a patient with a Bla(kpc-2)-positive Klebsiella pneumoniae blood stream infection. Surg Infect (Larchmt). 2011 Aug; 12(4):325-7. PMID: 21859337.
      View in: PubMed
    142. Housman ST, Kuti JL, Nicolau DP. Optimizing antibiotic pharmacodynamics in hospital-acquired and ventilator-acquired bacterial pneumonia. Clin Chest Med. 2011 Sep; 32(3):439-50. PMID: 21867814.
      View in: PubMed
    143. Wiskirchen DE, Shepard A, Kuti JL, Nicolau DP. Determination of tissue penetration and pharmacokinetics of linezolid in patients with diabetic foot infections using in vivo microdialysis. Antimicrob Agents Chemother. 2011 Sep; 55(9):4170-5. PMID: 21709078; PMCID: PMC3165366.
    144. Keel RA, Crandon JL, Nicolau DP. Efficacy of human simulated exposures of ceftaroline administered at 600 milligrams every 12 hours against phenotypically diverse Staphylococcus aureus isolates. Antimicrob Agents Chemother. 2011 Sep; 55(9):4028-32. PMID: 21670184; PMCID: PMC3165327.
    145. Sutherland CA, Nicolau DP, Kuti JL. Development of an HPLC method for the determination of anidulafungin in human plasma and saline. J Chromatogr Sci. 2011 May; 49(5):397-400. PMID: 21549032.
      View in: PubMed
    146. Keel RA, Schaeftlein A, Kloft C, Pope JS, Knauft RF, Muhlebach M, Nicolau DP, Kuti JL. Pharmacokinetics of intravenous and oral linezolid in adults with cystic fibrosis. Antimicrob Agents Chemother. 2011 Jul; 55(7):3393-8. PMID: 21518837; PMCID: PMC3122391.
    147. Wiskirchen DE, Crandon JL, Furtado GH, Williams G, Nicolau DP. In vivo efficacy of a human-simulated regimen of ceftaroline combined with NXL104 against extended-spectrum-beta-lactamase (ESBL)-producing and non-ESBL-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2011 Jul; 55(7):3220-5. PMID: 21518838; PMCID: PMC3122417.
    148. Eagye KJ, Nicolau DP. Change in antipseudomonal carbapenem susceptibility in 25 hospitals across 9 years is not associated with the use of ertapenem. J Antimicrob Chemother. 2011 Jun; 66(6):1392-5. PMID: 21459897.
      View in: PubMed
    149. Eagye KJ, Nicolau DP. Fluoroquinolone use is not associated with the change in imipenem susceptibility of Pseudomonas aeruginosa in 25 hospitals. Adv Ther. 2011 Apr; 28(4):326-33. PMID: 21445549.
      View in: PubMed
    150. Bulik CC, Nicolau DP. Double-carbapenem therapy for carbapenemase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2011 Jun; 55(6):3002-4. PMID: 21422205; PMCID: PMC3101469.
    151. Nicolau DP. Current challenges in the management of the infected patient. Curr Opin Infect Dis. 2011 Feb; 24 Suppl 1:S1-10. PMID: 21200179.
      View in: PubMed
    152. Wiskirchen DE, Koomanachai P, Nicasio AM, Nicolau DP, Kuti JL. In vitro pharmacodynamics of simulated pulmonary exposures of tigecycline alone and in combination against Klebsiella pneumoniae isolates producing a KPC carbapenemase. Antimicrob Agents Chemother. 2011 Apr; 55(4):1420-7. PMID: 21282442; PMCID: PMC3067181.
    153. Koomanachai P, Keel RA, Johnson-Arbor KK, Suecof LA, Nicolau DP, Kuti JL. Linezolid penetration into wound tissue of two diabetic patients before and after hyperbaric oxygen therapy. Undersea Hyperb Med. 2011 Jan-Feb; 38(1):11-6. PMID: 21384759.
      View in: PubMed
    154. Keel RA, Zhanel GG, Zelenitsky S, Nicolau DP. Pharmacodynamic profiling of antimicrobials against Gram-negative respiratory isolates from Canadian hospitals. Can J Infect Dis Med Microbiol. 2011; 22(4):132-6. PMID: 23205024; PMCID: PMC3222759.
    155. Crandon JL, Nicolau DP. Pharmacodynamic approaches to optimizing beta-lactam therapy. Crit Care Clin. 2011 Jan; 27(1):77-93. PMID: 21144987.
      View in: PubMed
    156. Roberts JA, Kwa A, Montakantikul P, Gomersall C, Kuti JL, Nicolau DP. Pharmacodynamic profiling of intravenous antibiotics against prevalent Gram-negative organisms across the globe: the PASSPORT Program-Asia-Pacific Region. Int J Antimicrob Agents. 2011 Mar; 37(3):225-9. PMID: 21168997.
      View in: PubMed
    157. Crandon JL, Ariano RE, Zelenitsky SA, Nicasio AM, Kuti JL, Nicolau DP. Optimization of meropenem dosage in the critically ill population based on renal function. Intensive Care Med. 2011 Apr; 37(4):632-8. PMID: 21136037.
      View in: PubMed
    158. Keel RA, Sutherland CA, Aslanzadeh J, Nicolau DP, Kuti JL. Correlation between vancomycin and daptomycin MIC values for methicillin-susceptible and methicillin-resistant Staphylococcus aureus by 3 testing methodologies. Diagn Microbiol Infect Dis. 2010 Nov; 68(3):326-9. PMID: 20955917.
      View in: PubMed
    159. Bulik CC, Wiskirchen DE, Shepard A, Sutherland CA, Kuti JL, Nicolau DP. Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis. Antimicrob Agents Chemother. 2010 Dec; 54(12):5209-13. PMID: 20921312; PMCID: PMC2981255.
    160. Furtado GH, Nicolau DP. Overview perspective of bacterial resistance. Expert Opin Ther Pat. 2010 Oct; 20(10):1273-6. PMID: 20687782.
      View in: PubMed
    161. Crandon JL, Sutherland C, Nicolau DP. Stability of doripenem in polyvinyl chloride bags and elastomeric pumps. Am J Health Syst Pharm. 2010 Sep 15; 67(18):1539-44. PMID: 20811032.
      View in: PubMed
    162. Crandon JL, Kuti JL, Nicolau DP. Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model. Antimicrob Agents Chemother. 2010 Dec; 54(12):5115-9. PMID: 20837760; PMCID: PMC2981287.
    163. Keel RA, Sutherland CA, Crandon JL, Nicolau DP. Stability of doripenem, imipenem and meropenem at elevated room temperatures. Int J Antimicrob Agents. 2011 Feb; 37(2):184-5. PMID: 20702066.
      View in: PubMed
    164. Bulik CC, Nicolau DP. In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2010 Oct; 54(10):4112-5. PMID: 20660688; PMCID: PMC2944615.
    165. Kim A, Nicolau DP, Kuti JL. Hospital costs and outcomes among intravenous antifungal therapies for patients with invasive aspergillosis in the United States. Mycoses. 2011 Sep; 54(5):e301-12. PMID: 20557463.
      View in: PubMed
    166. Bulik CC, Fauntleroy KA, Jenkins SG, Abuali M, LaBombardi VJ, Nicolau DP, Kuti JL. Comparison of meropenem MICs and susceptibilities for carbapenemase-producing Klebsiella pneumoniae isolates by various testing methods. J Clin Microbiol. 2010 Jul; 48(7):2402-6. PMID: 20484603; PMCID: PMC2897473.
    167. Eagye KJ, Nicolau DP. Absence of association between use of ertapenem and change in antipseudomonal carbapenem susceptibility rates in 25 hospitals. Infect Control Hosp Epidemiol. 2010 May; 31(5):485-90. PMID: 20334550.
      View in: PubMed
    168. Nicasio AM, Eagye KJ, Kuti EL, Nicolau DP, Kuti JL. Length of stay and hospital costs associated with a pharmacodynamic-based clinical pathway for empiric antibiotic choice for ventilator-associated pneumonia. Pharmacotherapy. 2010 May; 30(5):453-62. PMID: 20411997.
      View in: PubMed
    169. Koomanachai P, Bulik CC, Kuti JL, Nicolau DP. Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States. Clin Ther. 2010 Apr; 32(4):766-79. PMID: 20435246.
      View in: PubMed
    170. Kuti JL, Nicolau DP. Optimal cefepime and meropenem dosing for ventilator-associated pneumonia patients with reduced renal function: an update to our clinical pathway. J Crit Care. 2010 Mar; 25(1):155-6. PMID: 20189057.
      View in: PubMed
    171. Ray L, Levasseur K, Nicolau DP, Scheetz MH. Cerebral spinal fluid penetration of tigecycline in a patient with Acinetobacter baumannii cerebritis. Ann Pharmacother. 2010 Mar; 44(3):582-6. PMID: 20179255.
      View in: PubMed
    172. Nicolau DP, Stein GE. Therapeutic options for diabetic foot infections: a review with an emphasis on tissue penetration characteristics. J Am Podiatr Med Assoc. 2010 Jan-Feb; 100(1):52-63. PMID: 20093545.
      View in: PubMed
    173. Crandon JL, Bulik CC, Kuti JL, Nicolau DP. Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2010 Mar; 54(3):1111-6. PMID: 20038614; PMCID: PMC2825990.
    174. Bulik CC, Christensen H, Li P, Sutherland CA, Nicolau DP, Kuti JL. Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob Agents Chemother. 2010 Feb; 54(2):804-10. PMID: 19995927; PMCID: PMC2812157.
    175. Koomanachai P, Crandon JL, Nicolau DP. Newer developments in the treatment of Gram-positive infections. Expert Opin Pharmacother. 2009 Dec; 10(17):2829-43. PMID: 19929705.
      View in: PubMed
    176. Bulik CC, Christensen H, Nicolau DP. In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance. Antimicrob Agents Chemother. 2010 Jan; 54(1):557-9. PMID: 19917762; PMCID: PMC2798502.
    177. Kim A, Kuti JL, Nicolau DP. Probability of pharmacodynamic target attainment with standard and prolonged-infusion antibiotic regimens for empiric therapy in adults with hospital-acquired pneumonia. Clin Ther. 2009 Nov; 31(11):2765-78. PMID: 20110018.
      View in: PubMed
    178. Eagye KJ, Kuti JL, Sutherland CA, Christensen H, Nicolau DP. In vitro activity and pharmacodynamics of commonly used antibiotics against adult systemic isolates of Escherichia coli and Pseudomonas aeruginosa at Forty US Hospitals. Clin Ther. 2009 Nov; 31(11):2678-88. PMID: 20110010.
      View in: PubMed
    179. Crandon JL, Bulik CC, Nicolau DP. In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2009 Oct; 53(10):4352-6. PMID: 19770286; PMCID: PMC2764160.
    180. Kontou P, Kuti JL, Nicolau DP. Validation of the Infectious Diseases Society of America/American Thoracic Society criteria to predict severe community-acquired pneumonia caused by Streptococcus pneumoniae. Am J Emerg Med. 2009 Oct; 27(8):968-74. PMID: 19857416.
      View in: PubMed
    181. Crandon JL, Banevicius MA, Fang AF, Crownover PH, Knauft RF, Pope JS, Russomanno JH, Shore E, Nicolau DP, Kuti JL. Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults. Antimicrob Agents Chemother. 2009 Dec; 53(12):5102-7. PMID: 19770284; PMCID: PMC2786330.
    182. Koomanachai P, Crandon JL, Banevicius MA, Peng L, Nicolau DP. Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model. Antimicrob Agents Chemother. 2009 Dec; 53(12):5060-3. PMID: 19738006; PMCID: PMC2786358.
    183. Courter JD, Kuti JL, Girotto JE, Nicolau DP. Optimizing bactericidal exposure for beta-lactams using prolonged and continuous infusions in the pediatric population. Pediatr Blood Cancer. 2009 Sep; 53(3):379-85. PMID: 19422028.
      View in: PubMed
    184. Crandon JL, Kim A, Nicolau DP. Comparison of tigecycline penetration into the epithelial lining fluid of infected and uninfected murine lungs. J Antimicrob Chemother. 2009 Oct; 64(4):837-9. PMID: 19696049.
      View in: PubMed
    185. Eagye KJ, Kim A, Laohavaleeson S, Kuti JL, Nicolau DP. Surgical site infections: does inadequate antibiotic therapy affect patient outcomes? Surg Infect (Larchmt). 2009 Aug; 10(4):323-31. PMID: 19622027.
      View in: PubMed
    186. Eagye KJ, Kuti JL, Nicolau DP. Risk factors and outcomes associated with isolation of meropenem high-level-resistant Pseudomonas aeruginosa. Infect Control Hosp Epidemiol. 2009 Aug; 30(8):746-52. PMID: 19583513.
      View in: PubMed
    187. Bulik CC, Kuti JL, Nicolau DP. Clostridium difficile infection--not just a burden anymore. Conn Med. 2009 Aug; 73(7):407-11. PMID: 19708320.
      View in: PubMed
    188. Nicolau DP. What is the 360-degree approach to defining success for VAP? J Manag Care Pharm. 2009 Jun; 15(5 Suppl):S3-4. PMID: 19505172.
      View in: PubMed
    189. Kuti JL, Nicasio AM, Sutherland CA, Nicolau DP. Elevated vancomycin minimum inhibitory concentrations among methicillin-resistant Staphylococcus aureus isolated from patients with ventilator-associated pneumonia at a Connecticut hospital. Conn Med. 2009 Jun-Jul; 73(6):337-40. PMID: 19637663.
      View in: PubMed
    190. Rodvold KA, Nicolau DP, Lodise TP, Khashab M, Noel GJ, Kahn JB, Gotfried M, Murray SA, Nicholson S, Laohavaleeson S, Tessier PR, Drusano GL. Identifying exposure targets for treatment of staphylococcal pneumonia with ceftobiprole. Antimicrob Agents Chemother. 2009 Aug; 53(8):3294-301. PMID: 19451287; PMCID: PMC2715607.
    191. Nicasio AM, Eagye KJ, Nicolau DP, Shore E, Palter M, Pepe J, Kuti JL. Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia. J Crit Care. 2010 Mar; 25(1):69-77. PMID: 19427167.
      View in: PubMed
    192. Nicolau DP. Management of complicated infections in the era of antimicrobial resistance: the role of tigecycline. Expert Opin Pharmacother. 2009 May; 10(7):1213-22. PMID: 19405794.
      View in: PubMed
    193. Nicasio AM, Crandon JL, Nicolau DP. In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates. Antimicrob Agents Chemother. 2009 Jul; 53(7):2756-61. PMID: 19364850; PMCID: PMC2704680.
    194. Eagye KJ, Nicolau DP. Deep and organ/space infections in patients undergoing elective colorectal surgery: incidence and impact on hospital length of stay and costs. Am J Surg. 2009 Sep; 198(3):359-67. PMID: 19306972.
      View in: PubMed
    195. Koomanachai P, Kim A, Nicolau DP. Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model. J Antimicrob Chemother. 2009 May; 63(5):982-7. PMID: 19279050.
      View in: PubMed
    196. Nicolau DP. Containing costs and containing bugs: are they mutually exclusive? J Manag Care Pharm. 2009 Mar; 15(2 Suppl):S12-7. PMID: 19236136.
      View in: PubMed
    197. Eagye KJ, Nicolau DP, Kuti JL. Impact of superinfection on hospital length of stay and costs in patients with ventilator-associated pneumonia. Semin Respir Crit Care Med. 2009 Feb; 30(1):116-23. PMID: 19199193.
      View in: PubMed
    198. Kuti JL, Shore E, Palter M, Nicolau DP. Tackling empirical antibiotic therapy for ventilator-associated pneumonia in your ICU: guidance for implementing the guidelines. Semin Respir Crit Care Med. 2009 Feb; 30(1):102-15. PMID: 19199192.
      View in: PubMed
    199. Crandon JL, Kuti JL, Jones RN, Nicolau DP. Comparison of 2002-2006 OPTAMA programs for US hospitals: focus on gram-negative resistance. Ann Pharmacother. 2009 Feb; 43(2):220-7. PMID: 19193582.
      View in: PubMed
    200. Nicasio AM, Ariano RE, Zelenitsky SA, Kim A, Crandon JL, Kuti JL, Nicolau DP. Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia. Antimicrob Agents Chemother. 2009 Apr; 53(4):1476-81. PMID: 19188394; PMCID: PMC2663089.
    201. Nicasio AM, Tessier PR, Nicolau DP, Knauft RF, Russomanno J, Shore E, Kuti JL. Bronchopulmonary disposition of micafungin in healthy adult volunteers. Antimicrob Agents Chemother. 2009 Mar; 53(3):1218-20. PMID: 19114675; PMCID: PMC2650581.
    202. Crandon JL, Banevicius MA, Nicolau DP. Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model. Antimicrob Agents Chemother. 2009 Mar; 53(3):1165-9. PMID: 19114676; PMCID: PMC2650523.
    203. Koomanachai P, Crandon JL, Kuti JL, Nicolau DP. Comparative pharmacodynamics for intravenous antibiotics against Gram-negative bacteria in Europe between 2002 and 2006: a report from the OPTAMA program. Int J Antimicrob Agents. 2009 Apr; 33(4):348-53. PMID: 19091515.
      View in: PubMed
    204. Laohavaleeson S, Barriere SL, Nicolau DP, Kuti JL. Cost-effectiveness of telavancin versus vancomycin for treatment of complicated skin and skin structure infections. Pharmacotherapy. 2008 Dec; 28(12):1471-82. PMID: 19025428.
      View in: PubMed
    205. Laohavaleeson S, Lolans K, Quinn JP, Kuti JL, Nicolau DP. Expression of the MexXY-OprM efflux system in Pseudomonas aeruginosa with discordant cefepime/ceftazidime susceptibility profiles. Infect Drug Resist. 2008; 1:51-5. PMID: 21694880; PMCID: PMC3108718.
    206. Nicolau DP. Pharmacokinetic and pharmacodynamic properties of meropenem. Clin Infect Dis. 2008 Sep 15; 47 Suppl 1:S32-40. PMID: 18713048.
      View in: PubMed
    207. Kim A, Suecof LA, Sutherland CA, Gao L, Kuti JL, Nicolau DP. In vivo microdialysis study of the penetration of daptomycin into soft tissues in diabetic versus healthy volunteers. Antimicrob Agents Chemother. 2008 Nov; 52(11):3941-6. PMID: 18779352; PMCID: PMC2573116.
    208. Nicasio AM, Kuti JL, Aslanzadeh J, Nicolau DP. Influence of automated screening and confirmation of extended-spectrum beta-lactamase-producing members of the Enterobacteriaceae on prescribing of antibiotics. J Med Microbiol. 2008 Sep; 57(Pt 9):1147-51. PMID: 18719186.
      View in: PubMed
    209. Stein GE, Schooley SL, Nicolau DP. Urinary bactericidal activity of single doses (250, 500, 750 and 1000 mg) of levofloxacin against fluoroquinolone-resistant strains of Escherichia coli. Int J Antimicrob Agents. 2008 Oct; 32(4):320-5. PMID: 18715762.
      View in: PubMed
    210. Beneri CA, Nicolau DP, Seiden HS, Rubin LG. Successful treatment of a neonate with persistent vancomycin-resistant enterococcal bacteremia with a daptomycin-containing regimen. Infect Drug Resist. 2008; 1:9-11. PMID: 21694874; PMCID: PMC3108720.
    211. Charifson PS, Grillot AL, Grossman TH, Parsons JD, Badia M, Bellon S, Deininger DD, Drumm JE, Gross CH, LeTiran A, Liao Y, Mani N, Nicolau DP, Perola E, Ronkin S, Shannon D, Swenson LL, Tang Q, Tessier PR, Tian SK, Trudeau M, Wang T, Wei Y, Zhang H, Stamos D. Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: intelligent design and evolution through the judicious use of structure-guided design and structure-activity relationships. J Med Chem. 2008 Sep 11; 51(17):5243-63. PMID: 18690678.
      View in: PubMed
    212. Crandon J, Nicolau DP. Oritavancin: a potential weapon in the battle against serious Gram-positive pathogens. Future Microbiol. 2008 Jun; 3(3):251-63. PMID: 18505390.
      View in: PubMed
    213. Nicolau DP. Pharmacodynamic optimization of beta-lactams in the patient care setting. Crit Care. 2008; 12 Suppl 4:S2. PMID: 18495059; PMCID: PMC2391264.
    214. Kim A, Banevicius MA, Nicolau DP. In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. Antimicrob Agents Chemother. 2008 Jul; 52(7):2497-502. PMID: 18458125; PMCID: PMC2443926.
    215. Nicolau DP. Bugs versus drugs: what is the pharmacist's challenge? Am J Health Syst Pharm. 2008 May 1; 65(9 Suppl 2):S2-3. PMID: 18436736.
      View in: PubMed
    216. Laohavaleeson S, Tessier PR, Nicolau DP. Pharmacodynamic characterization of ceftobiprole in experimental pneumonia caused by phenotypically diverse Staphylococcus aureus strains. Antimicrob Agents Chemother. 2008 Jul; 52(7):2389-94. PMID: 18411322; PMCID: PMC2443930.
    217. Kim SW, Kuti JL, Nicolau DP. Inhaled antimicrobial therapies for respiratory infections. Curr Infect Dis Rep. 2008 Mar; 10(1):29-36. PMID: 18377812.
      View in: PubMed
    218. Nicasio AM, Kuti JL, Nicolau DP. The current state of multidrug-resistant gram-negative bacilli in North America. Pharmacotherapy. 2008 Feb; 28(2):235-49. PMID: 18225969.
      View in: PubMed
    219. Kuti JL, Dowzicky M, Nicolau DP. Pharmacodynamic performance of tigecycline versus common intravenous antibiotics for the empiric treatment of complicated skin and skin structure infections. Surg Infect (Larchmt). 2008 Feb; 9(1):57-66. PMID: 18363469.
      View in: PubMed
    220. Nicolau DP. Carbapenems: a potent class of antibiotics. Expert Opin Pharmacother. 2008 Jan; 9(1):23-37. PMID: 18076336.
      View in: PubMed
    221. Fallon RM, Kuti JL, Doern GV, Girotto JE, Nicolau DP. Pharmacodynamic target attainment of oral beta-lactams for the empiric treatment of acute otitis media in children. Paediatr Drugs. 2008; 10(5):329-35. PMID: 18754699.
      View in: PubMed
    222. Pichichero ME, Doern GV, Kuti JL, Nicolau DP. Probability of achieving requisite pharmacodynamic exposure for oral beta-lactam regimens against Haemophilus influenzae in children. Paediatr Drugs. 2008; 10(6):391-7. PMID: 18998749.
      View in: PubMed
    223. Kim A, Sutherland CA, Kuti JL, Nicolau DP. Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion? Pharmacotherapy. 2007 Nov; 27(11):1490-7. PMID: 17963458.
      View in: PubMed
    224. Stein GE, Schooley S, Tyrrell KL, Citron DM, Nicolau DP, Goldstein EJ. Serum bactericidal activities of moxifloxacin and levofloxacin against aerobic and anaerobic intra-abdominal pathogens. Anaerobe. 2008 Feb; 14(1):8-12. PMID: 17983770.
      View in: PubMed
    225. Eagye KJ, Nicolau DP, Lockhart SR, Quinn JP, Doern GV, Gallagher G, Abramson MA. A pharmacodynamic analysis of resistance trends in pathogens from patients with infection in intensive care units in the United States between 1993 and 2004. Ann Clin Microbiol Antimicrob. 2007; 6:11. PMID: 17908321; PMCID: PMC2134929.
    226. Newman D, Scheetz MH, Adeyemi OA, Montevecchi M, Nicolau DP, Noskin GA, Postelnick MJ. Serum piperacillin/tazobactam pharmacokinetics in a morbidly obese individual. Ann Pharmacother. 2007 Oct; 41(10):1734-9. PMID: 17726066.
      View in: PubMed
    227. Wang H, Zhang B, Ni Y, Kuti JL, Chen B, Chen M, Nicolau DP. Pharmacodynamic target attainment of seven antimicrobials against Gram-negative bacteria collected from China in 2003 and 2004. Int J Antimicrob Agents. 2007 Nov; 30(5):452-7. PMID: 17646088.
      View in: PubMed
    228. Nicolau DP, Sun HK, Seltzer E, Buckwalter M, Dowell JA. Pharmacokinetics of dalbavancin in plasma and skin blister fluid. J Antimicrob Chemother. 2007 Sep; 60(3):681-4. PMID: 17631507.
      View in: PubMed
    229. Nicasio AM, Quintiliani R, DeRyke CA, Kuti JL, Nicolau DP. Treatment of Serratia marcescens meningitis with prolonged infusion of meropenem. Ann Pharmacother. 2007 Jun; 41(6):1077-81. PMID: 17472997.
      View in: PubMed
    230. Kim A, Kuti JL, Nicolau DP. Review of dalbavancin, a novel semisynthetic lipoglycopeptide. Expert Opin Investig Drugs. 2007 May; 16(5):717-33. PMID: 17461743.
      View in: PubMed
    231. Eagye KJ, Kuti JL, Dowzicky M, Nicolau DP. Empiric therapy for secondary peritonitis: a pharmacodynamic analysis of cefepime, ceftazidime, ceftriaxone, imipenem, levofloxacin, piperacillin/tazobactam, and tigecycline using Monte Carlo simulation. Clin Ther. 2007 May; 29(5):889-99. PMID: 17697907.
      View in: PubMed
    232. Eagye KJ, Kuti JL, Nicolau DP. Evaluating empiric treatment options for secondary peritonitis using pharmacodynamic profiling. Surg Infect (Larchmt). 2007 Apr; 8(2):215-26. PMID: 17437367.
      View in: PubMed
    233. Kiffer CR, Kuti JL, Mendes CM, Oplustil CP, Amarante JB, Biancalana ML, Xavier N, Nicolau DP. A pharmacodynamic strategy to optimize empirical antibiotic therapy for gram-negative bacteria in a Brazilian Intensive Care Unit. Braz J Infect Dis. 2007 Apr; 11(2):183-5. PMID: 17625756.
      View in: PubMed
    234. Sutherland C, Nicolau DP. Development of an HPLC method for the determination of doripenem in human and mouse serum. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Jun 15; 853(1-2):123-6. PMID: 17392039.
      View in: PubMed
    235. DeRyke CA, Kuti JL, Nicolau DP. Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessment. Diagn Microbiol Infect Dis. 2007 Jul; 58(3):337-44. PMID: 17350206.
      View in: PubMed
    236. Laohavaleeson S, Kuti JL, Nicolau DP. Telavancin: a novel lipoglycopeptide for serious gram-positive infections. Expert Opin Investig Drugs. 2007 Mar; 16(3):347-57. PMID: 17302529.
      View in: PubMed
    237. DeRyke CA, Kuti JL, Nicolau DP. Pharmacodynamic target attainment of six beta-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States intensive care units in 2004. Pharmacotherapy. 2007 Mar; 27(3):333-42. PMID: 17316145.
      View in: PubMed
    238. Li C, Du X, Kuti JL, Nicolau DP. Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother. 2007 May; 51(5):1725-30. PMID: 17307978; PMCID: PMC1855547.
    239. DeRyke CA, Banevicius MA, Fan HW, Nicolau DP. Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model. Antimicrob Agents Chemother. 2007 Apr; 51(4):1481-6. PMID: 17283197; PMCID: PMC1855479.
    240. Kioumis IP, Kuti JL, Nicolau DP. Intra-abdominal infections: considerations for the use of the carbapenems. Expert Opin Pharmacother. 2007 Feb; 8(2):167-82. PMID: 17257087.
      View in: PubMed
    241. DeRyke CA, Nicolau DP. Is all free time above the minimum inhibitory concentration the same: implications for beta-lactam in vivo modelling. Int J Antimicrob Agents. 2007 Mar; 29(3):341-3. PMID: 17223318.
      View in: PubMed
    242. Sun HK, Du X, DeRyke CA, Doern GV, Nicolau DP. parE mutations in Streptococcus pneumoniae may reduce bactericidal activity of respiratory fluoroquinolones. Int J Antimicrob Agents. 2007 Feb; 29(2):230-2. PMID: 17204405.
      View in: PubMed
    243. Nicolau DP, Sutherland CA, Arguedas A, Dagan R, Pichichero ME. Pharmacokinetics of cefprozil in plasma and middle ear fluid: in children undergoing treatment for acute otitis media. Paediatr Drugs. 2007; 9(2):119-23. PMID: 17407367.
      View in: PubMed
    244. Lee SY, Fan HW, Sutherland C, DeRyke AC, Nicolau DP. Antibacterial effects of moxifloxacin and levofloxacin simulating epithelial lining fluid concentrations against community-acquired methicillin-resistant Staphylococcus aureus. Drugs R D. 2007; 8(2):69-77. PMID: 17324004.
      View in: PubMed
    245. Lee SY, Tessier PR, Murphy CK, Nicolau DP. Bactericidal efficacy of ABI-0043, a novel rifamycin, in a murine pneumococcal pneumonia model. J Antibiot (Tokyo). 2006 Dec; 59(12):804-7. PMID: 17323649.
      View in: PubMed
    246. Ludwig E, Konkoly-Thege M, Kuti JL, Nicolau DP. Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals. Int J Antimicrob Agents. 2006 Nov; 28(5):433-8. PMID: 17046212.
      View in: PubMed
    247. DeRyke CA, Sutherland C, Zhang B, Nicolau DP, Kuti JL. Serum bactericidal activities of high-dose daptomycin with and without coadministration of gentamicin against isolates of Staphylococcus aureus and Enterococcus species. Antimicrob Agents Chemother. 2006 Nov; 50(11):3529-34. PMID: 17065618; PMCID: PMC1635189.
    248. Lee SY, Kuti JL, Nicolau DP. Cefepime pharmacodynamics in patients with extended spectrum beta-lactamase (ESBL) and non-ESBL infections. J Infect. 2007 May; 54(5):463-8. PMID: 17067681.
      View in: PubMed
    249. Lee SY, Kotapati S, Kuti JL, Nightingale CH, Nicolau DP. Impact of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species on clinical outcomes and hospital costs: a matched cohort study. Infect Control Hosp Epidemiol. 2006 Nov; 27(11):1226-32. PMID: 17080381.
      View in: PubMed
    250. Scheetz MH, Reddy P, Nicolau DP, Noskin GA, Postelnick MJ, Stosor V, Zembower TR. Peritoneal fluid penetration of tigecycline. Ann Pharmacother. 2006 Nov; 40(11):2064-7. PMID: 17047138.
      View in: PubMed
    251. Li C, Kuti JL, Nightingale CH, Nicolau DP. Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. J Clin Pharmacol. 2006 Oct; 46(10):1171-8. PMID: 16988206.
      View in: PubMed
    252. Sun HK, Nicolau DP, Kuti JL. Resource utilization of adults admitted to a large urban hospital with community-acquired pneumonia caused by Streptococcus pneumoniae. Chest. 2006 Sep; 130(3):807-14. PMID: 16963679.
      View in: PubMed
    253. Lau WK, Mercer D, Itani KM, Nicolau DP, Kuti JL, Mansfield D, Dana A. Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection. Antimicrob Agents Chemother. 2006 Nov; 50(11):3556-61. PMID: 16940077; PMCID: PMC1635208.
    254. Ong CT, Tessier PR, Li C, Nightingale CH, Nicolau DP. Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps. Diagn Microbiol Infect Dis. 2007 Feb; 57(2):153-61. PMID: 16930925.
      View in: PubMed
    255. Kiffer CR, Kuti JL, Eagye KJ, Mendes C, Nicolau DP. Pharmacodynamic profiling of imipenem, meropenem and ertapenem against clinical isolates of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. from Brazil. Int J Antimicrob Agents. 2006 Oct; 28(4):340-4. PMID: 16930951.
      View in: PubMed
    256. Deryke CA, Du X, Nicolau DP. Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae. J Antimicrob Chemother. 2006 Sep; 58(3):601-9. PMID: 16857688.
      View in: PubMed
    257. Lee SY, Fan HW, Kuti JL, Nicolau DP. Update on daptomycin: the first approved lipopeptide antibiotic. Expert Opin Pharmacother. 2006 Jul; 7(10):1381-97. PMID: 16805723.
      View in: PubMed
    258. Kuti JL, Ong C, Lo M, Melnick D, Soto N, Nicolau DP. Comparison of probability of target attainment calculated by Monte Carlo simulation with meropenem clinical and microbiological response for the treatment of complicated skin and skin structure infections. Int J Antimicrob Agents. 2006 Jul; 28(1):62-8. PMID: 16759839.
      View in: PubMed
    259. DeRyke CA, Kuti JL, Mansfield D, Dana A, Nicolau DP. Pharmacoeconomics of continuous versus intermittent infusion of piperacillin-tazobactam for the treatment of complicated intraabdominal infection. Am J Health Syst Pharm. 2006 Apr 15; 63(8):750-5. PMID: 16595817.
      View in: PubMed
    260. Niclau DP, Tessier pR, Rubinstein I, Nightingale CH. In vivo immunomodulatory profile of telithromycin in a murine pneumococcal infection model. Pharmazie. 2006 Apr; 61(4):343-7. PMID: 16649552.
      View in: PubMed
    261. Sun HK, Duchin K, Nightingale CH, Shaw JP, Seroogy J, Nicolau DP. Tissue penetration of telavancin after intravenous administration in healthy subjects. Antimicrob Agents Chemother. 2006 Feb; 50(2):788-90. PMID: 16436747; PMCID: PMC1366897.
    262. Du X, Li C, Kuti JL, Nightingale CH, Nicolau DP. Population pharmacokinetics and pharmacodynamics of meropenem in pediatric patients. J Clin Pharmacol. 2006 Jan; 46(1):69-75. PMID: 16397286.
      View in: PubMed
    263. DeRyke CA, Lee SY, Kuti JL, Nicolau DP. Optimising dosing strategies of antibacterials utilising pharmacodynamic principles: impact on the development of resistance. Drugs. 2006; 66(1):1-14. PMID: 16398565.
      View in: PubMed
    264. Lee SY, Kuti JL, Nicolau DP. Polymyxins: older antibiotics for a new threat. Conn Med. 2006 Jan; 70(1):25-8. PMID: 16479873.
      View in: PubMed
    265. Ellis JM, Kuti JL, Nicolau DP. Pharmacodynamic evaluation of meropenem and cefotaxime for pediatric meningitis: a report from the OPTAMA program. Paediatr Drugs. 2006; 8(2):131-8. PMID: 16608373.
      View in: PubMed
    266. Kuti JL, Nicolau DP. Making the most of surveillance studies: summary of the OPTAMA Program. Diagn Microbiol Infect Dis. 2005 Dec; 53(4):281-7. PMID: 16360552.
      View in: PubMed
    267. Brook I, Giraldo DE, Germana A, Nicolau DP, Jackson WE, Elliott TB, Thakar JH, Shoemaker MO, Ledney GD. Comparison of clarithromycin and ciprofloxacin therapy for Bacillus anthracis Sterne infection in mice with or without (60)Co gamma-photon irradiation. J Med Microbiol. 2005 Dec; 54(Pt 12):1157-62. PMID: 16278429.
      View in: PubMed
    268. Ellis JM, Kuti JL, Nicolau DP. Use of Monte Carlo simulation to assess the pharmacodynamics of beta-lactams against Pseudomonas aeruginosa infections in children: a report from the OPTAMA program. Clin Ther. 2005 Nov; 27(11):1820-30. PMID: 16368453.
      View in: PubMed
    269. Dandekar PK, Tessier PR, Farrell DJ, Nightingale CH, Nicolau DP. Evaluation of telithromycin against Streptococcus pneumoniae with ribosomal mutations utilizing in vitro time-kill methodology. Int J Antimicrob Agents. 2005 Oct; 26(4):331-4. PMID: 16144757.
      View in: PubMed
    270. Gillespie EL, Kuti JL, Nicolau DP. Pharmacodynamics of antimicrobials: treatment optimisation. Expert Opin Drug Metab Toxicol. 2005 Oct; 1(3):351-61. PMID: 16863448.
      View in: PubMed
    271. Kotapati S, Kuti JL, Nightingale CH, Nicolau DP. Clinical implications of extended spectrum beta-lactamase (ESBL) producing Klebsiella species and Escherichia coli on cefepime effectiveness. J Infect. 2005 Oct; 51(3):211-7. PMID: 16230218.
      View in: PubMed
    272. Sun HK, Kuti JL, Nicolau DP. Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program. Crit Care Med. 2005 Oct; 33(10):2222-7. PMID: 16215374.
      View in: PubMed
    273. Du X, Li C, Sun HK, Nightingale CH, Nicolau DP. A sensitive assay of amoxicillin in mouse serum and broncho-alveolar lavage fluid by liquid-liquid extraction and reversed-phase HPLC. J Pharm Biomed Anal. 2005 Sep 15; 39(3-4):648-52. PMID: 15935600.
      View in: PubMed
    274. Jacobson MA, Nicolau DP, Sutherland C, Smith A, Aweeka F. Pharmacokinetics of clarithromycin extended-release (ER) tablets in patients with AIDS. HIV Clin Trials. 2005 Sep-Oct; 6(5):246-53. PMID: 16306031.
      View in: PubMed
    275. Ong CT, Babalola CP, Nightingale CH, Nicolau DP. Penetration, efflux and intracellular activity of tigecycline in human polymorphonuclear neutrophils (PMNs). J Antimicrob Chemother. 2005 Sep; 56(3):498-501. PMID: 16024591.
      View in: PubMed
    276. Sun HK, Lee SY, Banevicius MA, Du X, Maglio D, Nicolau DP. Efficacy of pulsatile amoxicillin and clarithromycin dosing alone and in combination in a murine pneumococcal pneumonia model. J Antimicrob Chemother. 2005 Sep; 56(3):559-65. PMID: 16024590.
      View in: PubMed
    277. Li C, Kuti JL, Nightingale CH, Mansfield DL, Dana A, Nicolau DP. Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection. J Antimicrob Chemother. 2005 Aug; 56(2):388-95. PMID: 16002420.
      View in: PubMed
    278. Maglio D, Kuti JL, Nicolau DP. Simulation of antibiotic pharmacodynamic exposure for the empiric treatment of nosocomial bloodstream infections: a report from the OPTAMA program. Clin Ther. 2005 Jul; 27(7):1032-42. PMID: 16154482.
      View in: PubMed
    279. Kuti JL, Horowitz S, Nightingale CH, Nicolau DP. Comparison of pharmacodynamic target attainment between healthy subjects and patients for ceftazidime and meropenem. Pharmacotherapy. 2005 Jul; 25(7):935-41. PMID: 16006272.
      View in: PubMed
    280. Kuti JL, Nicolau DP. Derivation of meropenem dosage in patients receiving continuous veno-venous hemofiltration based on pharmacodynamic target attainment. Chemotherapy. 2005 Jul; 51(4):211-6. PMID: 15985760.
      View in: PubMed
    281. Dandekar PK, Williams P, Tessier PR, Farrell DJ, Nightingale CH, Nicolau DP. Assessment of the efficacy of telithromycin simulating human exposures against S. pneumoniae with ribosomal mutations in a murine pneumonia model. Int J Antimicrob Agents. 2005 Jun; 25(6):530-4. PMID: 15894464.
      View in: PubMed
    282. DeRyke CA, Maglio D, Nicolau DP. Defining the need for new antimicrobials: clinical and economic implications of resistance in the hospitalised patient. Expert Opin Pharmacother. 2005 Jun; 6(6):873-89. PMID: 15952918.
      View in: PubMed
    283. DeRyke CA, Kuti JL, Nicolau DP. Questioning the paradigm: monotherapy vs combination antimicrobial therapy for treatment of Pseudomonas aeruginosa. Conn Med. 2005 May; 69(5):271-5. PMID: 16114642.
      View in: PubMed
    284. Sun HK, Ong CT, Umer A, Harper D, Troy S, Nightingale CH, Nicolau DP. Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations. Antimicrob Agents Chemother. 2005 Apr; 49(4):1629-32. PMID: 15793157; PMCID: PMC1068611.
    285. Kotapati S, Kuti JL, Geissler EC, Nightingale CH, Nicolau DP. The clinical and economic benefits of administering piperacillin-tazobactam by continuous infusion. Intensive Crit Care Nurs. 2005 Apr; 21(2):87-93. PMID: 15778072.
      View in: PubMed
    286. Gillespie EL, Kuti JL, Nicolau DP. When "S" does not mean success: the importance of choice of antibiotic and dose on clinical and economic outcomes of severe infection. Conn Med. 2005 Apr; 69(4):203-10. PMID: 15926635.
      View in: PubMed
    287. Ong CT, Kuti JL, Nicolau DP. Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program. Surg Infect (Larchmt). 2005; 6(4):419-26. PMID: 16433606.
      View in: PubMed
    288. Fetterly GJ, Ong CM, Bhavnani SM, Loutit JS, Porter SB, Morello LG, Ambrose PG, Nicolau DP. Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose. Antimicrob Agents Chemother. 2005 Jan; 49(1):148-52. PMID: 15616289; PMCID: PMC538852.
    289. Tessier PR, Mattoes HM, Dandekar PK, Nightingale CH, Nicolau DP. Pharmacodynamic profile of telithromycin against macrolide- and fluoroquinolone-resistant Streptococcus pneumoniae in a neutropenic mouse thigh model. Antimicrob Agents Chemother. 2005 Jan; 49(1):188-94. PMID: 15616295; PMCID: PMC538883.
    290. Lee SY, Kuti JL, Nicolau DP. Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance. Surg Infect (Larchmt). 2005; 6(3):283-95. PMID: 16201938.
      View in: PubMed
    291. Maglio D, Banevicius MA, Sutherland C, Babalola C, Nightingale CH, Nicolau DP. Pharmacodynamic profile of ertapenem against Klebsiella pneumoniae and Escherichia coli in a murine thigh model. Antimicrob Agents Chemother. 2005 Jan; 49(1):276-80. PMID: 15616306; PMCID: PMC538873.
    292. Kotapati S, Kuti JL, Nicolau DP. Pharmacodynamic modeling of beta-lactam antibiotics for the empiric treatment of secondary peritonitis: a report from the OPTAMA program. Surg Infect (Larchmt). 2005; 6(3):297-304. PMID: 16201939.
      View in: PubMed
    293. Li C, Xuan D, Ye M, Nightingale CH, Nicolau DP. Simultaneous analysis of piperacillin and tazobactam in rabbits: application to pharmacokinetic study. Biomed Chromatogr. 2005 Jan; 19(1):99-106. PMID: 15484223.
      View in: PubMed
    294. Masterton RG, Kuti JL, Turner PJ, Nicolau DP. The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe. J Antimicrob Chemother. 2005 Jan; 55(1):71-7. PMID: 15574471.
      View in: PubMed
    295. Li C, Sutherland CA, Nightingale CH, Nicolau DP. Quantitation of tigecycline, a novel glycylcycline [corrected] by liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Nov 25; 811(2):225-9. PMID: 15522724.
      View in: PubMed
    296. Kuti JL, Moss KM, Nicolau DP, Knauft RF. Empiric treatment of multidrug-resistant Burkholderia cepacia lung exacerbation in a patient with cystic fibrosis: application of pharmacodynamic concepts to meropenem therapy. Pharmacotherapy. 2004 Nov; 24(11):1641-5. PMID: 15537567.
      View in: PubMed
    297. Sun H, Maglio D, Nicolau D. Macrolide resistance in Streptococcus pneumoniae: mechanisms, patterns, and clinical implications of resistance. Conn Med. 2004 Oct; 68(9):571-6. PMID: 15532438.
      View in: PubMed
    298. Nicolau DP. Treatment with appropriate antibiotic therapy in community-acquired respiratory tract infections. Am J Manag Care. 2004 Oct; 10(12 Suppl):S381-8. PMID: 15603247.
      View in: PubMed
    299. Babalola CP, Nightingale CH, Nicolau DP. Effect of adjunctive treatment with gamma interferon against Pseudomonas aeruginosa pneumonia in neutropenic and non-neutropenic hosts. Int J Antimicrob Agents. 2004 Sep; 24(3):219-25. PMID: 15325424.
      View in: PubMed
    300. Smith DL, Bauer SM, Nicolau DP. Stability of meropenem in polyvinyl chloride bags and an elastomeric infusion device. Am J Health Syst Pharm. 2004 Aug 15; 61(16):1682-5. PMID: 15540479.
      View in: PubMed
    301. Mattoes HM, Kuti JL, Drusano GL, Nicolau DP. Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem. Clin Ther. 2004 Aug; 26(8):1187-98. PMID: 15476901.
      View in: PubMed
    302. Kuti JL, Nightingale CH, Nicolau DP. Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: data collected in North America in 2002. Antimicrob Agents Chemother. 2004 Jul; 48(7):2464-70. PMID: 15215095; PMCID: PMC434188.
    303. Nicolau DP. Optimizing Efficacy in CARTIs: introduction. Ann Pharmacother. 2004 Sep; 38(9 Suppl):S7. PMID: 15226491.
      View in: PubMed
    304. Kotapati S, Nicolau DP, Nightingale CH, Kuti JL. Clinical and economic benefits of a meropenem dosage strategy based on pharmacodynamic concepts. Am J Health Syst Pharm. 2004 Jun 15; 61(12):1264-70. PMID: 15259757.
      View in: PubMed
    305. Maglio D, Ong C, Banevicius MA, Geng Q, Nightingale CH, Nicolau DP. Determination of the in vivo pharmacodynamic profile of cefepime against extended-spectrum-beta-lactamase-producing Escherichia coli at various inocula. Antimicrob Agents Chemother. 2004 Jun; 48(6):1941-7. PMID: 15155182; PMCID: PMC415572.
    306. Maglio D, Capitano B, Banevicius MA, Geng Q, Nightingale CH, Nicolau DP. Differential efficacy of clarithromycin in lung versus thigh infection models. Chemotherapy. 2004 Jun; 50(2):63-6. PMID: 15211079.
      View in: PubMed
    307. Kiffer CR, Mendes C, Kuti JL, Nicolau DP. Pharmacodynamic comparisons of antimicrobials against nosocomial isolates of escherichia coli, klebsiella pneumoniae, acinetobacter baumannii and pseudomonas aeruginosa from the MYSTIC surveillance program: the OPTAMA Program, South America 2002. Diagn Microbiol Infect Dis. 2004 Jun; 49(2):109-16. PMID: 15183860.
      View in: PubMed
    308. Capitano B, Nicolau DP, Potoski BA, Byers KE, Horowitz M, Venkataramanan R, Paterson DL. Meropenem administered as a prolonged infusion to treat serious gram-negative central nervous system infections. Pharmacotherapy. 2004 Jun; 24(6):803-7. PMID: 15222672.
      View in: PubMed
    309. Babalola CP, Nightingale CH, Nicolau DP. Adjunctive efficacy of granulocyte colony-stimulating factor on treatment of Pseudomonas aeruginosa pneumonia in neutropenic and non-neutropenic hosts. J Antimicrob Chemother. 2004 Jun; 53(6):1098-100. PMID: 15128727.
      View in: PubMed
    310. Dandekar PK, Tetreault J, Quinn JP, Nightingale CH, Nicolau DP. Prevalence of extended spectrum beta-lactamase producing Escherichia coli and Klebsiella isolates in a large community teaching hospital in Connecticut. Diagn Microbiol Infect Dis. 2004 May; 49(1):37-9. PMID: 15135498.
      View in: PubMed
    311. Maglio D, Capitano B, Banevicius MA, Tessier PR, Nightingale CH, Nicolau DP. Efficacy of clarithromycin against Streptococcus pneumoniae expressing mef(A)-mediated resistance. Int J Antimicrob Agents. 2004 May; 23(5):498-501. PMID: 15120730.
      View in: PubMed
    312. Kuti JL, Nightingale CH, Knauft RF, Nicolau DP. Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis. Clin Ther. 2004 Apr; 26(4):493-501. PMID: 15189746.
      View in: PubMed
    313. Babalola CP, Patel KB, Nightingale CH, Nicolau DP. Synergistic activity of vancomycin and teicoplanin alone and in combination with streptomycin against Enterococcus faecalis strains with various vancomycin susceptibilities. Int J Antimicrob Agents. 2004 Apr; 23(4):343-8. PMID: 15081082.
      View in: PubMed
    314. Florea NR, Tessier PR, Zhang C, Nightingale CH, Nicolau DP. Pharmacodynamics of moxifloxacin and levofloxacin at simulated epithelial lining fluid drug concentrations against Streptococcus pneumoniae. Antimicrob Agents Chemother. 2004 Apr; 48(4):1215-21. PMID: 15047522; PMCID: PMC375308.
    315. Dandekar PK, Tessier PR, Williams P, Zhang C, Nightingale CH, Nicolau DP. Determination of the pharmacodynamic profile of daptomycin against Streptococcus pneumoniae isolates with varying susceptibility to penicillin in a murine thigh infection model. Chemotherapy. 2004 Apr; 50(1):11-6. PMID: 15084799.
      View in: PubMed
    316. Xuan D, Nicolau DP, Nightingale CH. Population pharmacokinetics of gentamicin in hospitalized patients receiving once-daily dosing. Int J Antimicrob Agents. 2004 Mar; 23(3):291-5. PMID: 15164971.
      View in: PubMed
    317. Capitano B, Mattoes HM, Shore E, O'Brien A, Braman S, Sutherland C, Nicolau DP. Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. Chest. 2004 Mar; 125(3):965-73. PMID: 15006955.
      View in: PubMed
    318. Nicolau DP. Clinical use of antimicrobial pharmacodynamic profiles to optimise treatment outcomes in community-acquired bacterial respiratory tract infections: application to telithromycin. Expert Opin Pharmacother. 2004 Feb; 5(2):229-35. PMID: 14996620.
      View in: PubMed
    319. Amsden GW, Nicolau DP, Whitaker AM, Maglio D, Bello A, Russo R, Barros A, Gajjar DA. Characterization of the penetration of garenoxacin into the breast milk of lactating women. J Clin Pharmacol. 2004 Feb; 44(2):188-92. PMID: 14747428.
      View in: PubMed
    320. Li C, Nicolau DP, Lister PD, Quintiliani R, Nightingale CH. Pharmacodynamic study of beta-lactams alone and in combination with beta-lactamase inhibitors against Pseudomonas aeruginosa possessing an inducible beta-lactamase. J Antimicrob Chemother. 2004 Feb; 53(2):297-304. PMID: 14729755.
      View in: PubMed
    321. Ong CT, Kuti JL, Nightingale CH, Nicolau DP. Emerging Pseudomonas aeruginosa resistance: implications in clinical practice. Conn Med. 2004 Jan; 68(1):11-5. PMID: 14752913.
      View in: PubMed
    322. Kuti JL, Florea NR, Nightingale CH, Nicolau DP. Pharmacodynamics of meropenem and imipenem against Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa. Pharmacotherapy. 2004 Jan; 24(1):8-15. PMID: 14740783.
      View in: PubMed
    323. Kuti JL, Kotapati S, Williams P, Capitano B, Nightingale CH, Nicolau DP. Pharmacoeconomic analysis of amphotericin B lipid complex versus liposomal amphotericin B in the treatment of fungal infections. Pharmacoeconomics. 2004; 22(5):301-10. PMID: 15061680.
      View in: PubMed
    324. Nicolau DP. Optimizing outcomes with antimicrobial therapy through pharmacodynamic profiling. J Infect Chemother. 2003 Dec; 9(4):292-6. PMID: 14691648.
      View in: PubMed
    325. Capitano B, Maglio D, Banevicius MA, Nightingale CH, Nicolau DP. Bactericidal effect of cethromycin (ABT-773) in an immunocompetent murine pneumococcal pneumonia model. Int J Antimicrob Agents. 2003 Dec; 22(6):588-93. PMID: 14659656.
      View in: PubMed
    326. Zervos MJ, Hershberger E, Nicolau DP, Ritchie DJ, Blackner LK, Coyle EA, Donnelly AJ, Eckel SF, Eng RH, Hiltz A, Kuyumjian AG, Krebs W, McDaniel A, Hogan P, Lubowski TJ. Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991-2000. Clin Infect Dis. 2003 Dec 15; 37(12):1643-8. PMID: 14689346.
      View in: PubMed
    327. Florea NR, Kotapati S, Kuti JL, Geissler EC, Nightingale CH, Nicolau DP. Cost analysis of continuous versus intermittent infusion of piperacillin-tazobactam: a time-motion study. Am J Health Syst Pharm. 2003 Nov 15; 60(22):2321-7. PMID: 14652981.
      View in: PubMed
    328. Kuti JL, Dandekar PK, Nightingale CH, Nicolau DP. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J Clin Pharmacol. 2003 Oct; 43(10):1116-23. PMID: 14517194.
      View in: PubMed
    329. Li C, Geng Q, Nicolau DP, Nightingale CH. Simultaneous determination of ticarcillin and clavulanate in rabbit serum and tissue cage fluid by liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Sep 5; 794(2):227-36. PMID: 12954375.
      View in: PubMed
    330. Maglio D, Nicolau DP, Nightingale CH. Impact of pharmacodynamics on dosing of macrolides, azalides, and ketolides. Infect Dis Clin North Am. 2003 Sep; 17(3):563-77, vi. PMID: 14711077.
      View in: PubMed
    331. McNabb JJ, Nicolau DP, Stoner JA, Ross J. Patterns of adherence to antiretroviral medications: the value of electronic monitoring. AIDS. 2003 Aug 15; 17(12):1763-7. PMID: 12891062.
      View in: PubMed
    332. Dandekar PK, Tessier PR, Williams P, Nightingale CH, Nicolau DP. Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model. J Antimicrob Chemother. 2003 Sep; 52(3):405-11. PMID: 12917254.
      View in: PubMed
    333. Dandekar PK, Maglio D, Sutherland CA, Nightingale CH, Nicolau DP. Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion. Pharmacotherapy. 2003 Aug; 23(8):988-91. PMID: 12921245.
      View in: PubMed
    334. Maglio D, Nightingale CH, Nicolau DP. Production and resolution of cantharidin-induced inflammatory blisters. Int J Antimicrob Agents. 2003 Jul; 22(1):77-80. PMID: 12842333.
      View in: PubMed
    335. Kotapati S, Kuti JL, Nightingale CH, Nicolau DP. Role of pharmacodynamics in designing dosage regimens for beta-lactams. Conn Med. 2003 May; 67(5):265-8. PMID: 12802841.
      View in: PubMed
    336. Capitano B, Nicolau DP. Evolving epidemiology and cost of resistance to antimicrobial agents in long-term care facilities. J Am Med Dir Assoc. 2003 May-Jun; 4(3 Suppl):S90-9. PMID: 12854980.
      View in: PubMed
    337. Maglio D, Teng R, Thyrum PT, Nightingale CH, Nicolau DP. Pharmacokinetic profile of meropenem, administered at 500 milligrams every 8 hours, in plasma and cantharidin-induced skin blister fluid. Antimicrob Agents Chemother. 2003 May; 47(5):1771-3. PMID: 12709358; PMCID: PMC153322.
    338. Nicolau DP, Mattoes HM, Banevicius M, Xuan D, Nightingale CH. Pharmacodynamics of a novel des-F(6)-quinolone, BMS-284756, against Streptococcus pneumoniae in the thigh infection model. Antimicrob Agents Chemother. 2003 May; 47(5):1630-5. PMID: 12709332; PMCID: PMC153298.
    339. Kuti JL, Maglio D, Nightingale CH, Nicolau DP. Economic benefit of a meropenem dosage strategy based on pharmacodynamic concepts. Am J Health Syst Pharm. 2003 Mar 15; 60(6):565-8. PMID: 12659058.
      View in: PubMed
    340. Florea NR, Maglio D, Nicolau DP. Pleconaril, a novel antipicornaviral agent. Pharmacotherapy. 2003 Mar; 23(3):339-48. PMID: 12627933.
      View in: PubMed
    341. Florea NR, Kuti JL, Nightingale CH, Nicolau DP. Treatment of Clostridium difficile-associated disease (CDAD). Conn Med. 2003 Mar; 67(3):153-5. PMID: 12687790.
      View in: PubMed
    342. Dandekar PK, Barrett NL, Nightingale CH, Nicolau DP. Utilization of extended-spectrum beta-lactamase (ESBL) detection systems in microbiology laboratories: survey of Connecticut hospitals from 1998-2002. Conn Med. 2003 Mar; 67(3):149-52. PMID: 12687789.
      View in: PubMed
    343. Capitano B, Leshem OA, Nightingale CH, Nicolau DP. Cost effect of managing methicillin-resistant Staphylococcus aureus in a long-term care facility. J Am Geriatr Soc. 2003 Jan; 51(1):10-6. PMID: 12534839.
      View in: PubMed
    344. Kim MK, Nightingale C, Nicolau D. Influence of sex on the pharmacokinetic interaction of fleroxacin and ciprofloxacin with caffeine. Clin Pharmacokinet. 2003; 42(11):985-96. PMID: 12908854.
      View in: PubMed
    345. Dandekar PK, Nicolau DP. Pharmacodynamic considerations for the selection of oral cephalosporins in the treatment of rhinosinusitis. Otolaryngol Head Neck Surg. 2002 Dec; 127(6 Suppl):S10-6. PMID: 12511855.
      View in: PubMed
    346. Kuti JL, Le TN, Nightingale CH, Nicolau DP, Quintiliani R. Pharmacoeconomics of a pharmacist-managed program for automatically converting levofloxacin route from i.v. to oral. Am J Health Syst Pharm. 2002 Nov 15; 59(22):2209-15. PMID: 12455304.
      View in: PubMed
    347. Kim MK, Zhou W, Tessier PR, Xuan D, Ye M, Nightingale CH, Nicolau DP. Bactericidal effect and pharmacodynamics of cethromycin (ABT-773) in a murine pneumococcal pneumonia model. Antimicrob Agents Chemother. 2002 Oct; 46(10):3185-92. PMID: 12234843; PMCID: PMC128791.
    348. Kuti JL, Nightingale CH, Quintiliani R, Nicolau D. Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis. Diagn Microbiol Infect Dis. 2002 Sep; 44(1):51-7. PMID: 12376031.
      View in: PubMed
    349. Nicolau D. Clinical and economic implications of antimicrobial resistance for the management of community-acquired respiratory tract infections. J Antimicrob Chemother. 2002 Sep; 50 Suppl S1:61-70. PMID: 12239229.
      View in: PubMed
    350. Xuan D, Banevicius M, Capitano B, Kim MK, Nightingale C, Nicolau D. Pharmacodynamic assessment of ertapenem (MK-0826) against Streptococcus pneumoniae in a murine neutropenic thigh infection model. Antimicrob Agents Chemother. 2002 Sep; 46(9):2990-5. PMID: 12183258; PMCID: PMC127426.
    351. Kim MK, Capitano B, Mattoes HM, Xuan D, Quintiliani R, Nightingale CH, Nicolau DP. Pharmacokinetic and pharmacodynamic evaluation of two dosing regimens for piperacillin-tazobactam. Pharmacotherapy. 2002 May; 22(5):569-77. PMID: 12013355.
      View in: PubMed
    352. Mattoes HM, Capitano B, Kim MK, Xuan D, Quintiliani R, Nightingale CH, Nicolau DP. Comparative pharmacokinetic and pharmacodynamic profile of piperacillin/tazobactam 3.375G Q4H and 4.5G Q6H. Chemotherapy. 2002 May; 48(2):59-63. PMID: 12011536.
      View in: PubMed
    353. Tessier PR, Kim MK, Zhou W, Xuan D, Li C, Ye M, Nightingale CH, Nicolau DP. Pharmacodynamic assessment of clarithromycin in a murine model of pneumococcal pneumonia. Antimicrob Agents Chemother. 2002 May; 46(5):1425-34. PMID: 11959578; PMCID: PMC127127.
    354. Maglio D, Nightingale CH, Nicolau DP. Extended interval aminoglycoside dosing: from concept to clinic. Int J Antimicrob Agents. 2002 Apr; 19(4):341-8. PMID: 11978505.
      View in: PubMed
    355. Grant EM, Kuti JL, Nicolau DP, Nightingale C, Quintiliani R. Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital. Pharmacotherapy. 2002 Apr; 22(4):471-83. PMID: 11939682.
      View in: PubMed
    356. Nicolau DP. Pharmacodynamic rationale for short-duration antibacterial therapy. J Infect. 2002 Feb; 44 Suppl A:17-23. PMID: 12150491.
      View in: PubMed
    357. Xuan D, Ye M, Kim M, Nightingale CH, Nicolau DP. Pharmacokinetics of ABT-773, a new semi-synthetic ketolide in neutropenic lung-infected mice: a population approach. J Pharm Pharmacol. 2002 Jan; 54(1):71-5. PMID: 11829132.
      View in: PubMed
    358. Nicolau DP. Maximizing outcomes in respiratory tract infections in the age of resistance. Pharmacotherapy. 2002 Jan; 22(1 Pt 2):1S; discussion 30S-32S. PMID: 11791626.
      View in: PubMed
    359. Kuti JL, Capitano B, Nicolau DP. Cost-effective approaches to the treatment of community-acquired pneumonia in the era of resistance. Pharmacoeconomics. 2002; 20(8):513-28. PMID: 12109917.
      View in: PubMed
    360. Dandekar PK, Quintiliani R, Nightingale CH, Nicolau DP. Extended-spectrum beta-lactamases (ESBL). Conn Med. 2002 Jan; 66(1):13-5. PMID: 11852734.
      View in: PubMed
    361. Nicolau DP. Predicting antibacterial response from pharmacodynamic and pharmacokinetic profiles. Infection. 2001 Dec; 29 Suppl 2:11-5. PMID: 11785851.
      View in: PubMed
    362. Nicolau DP, Banevicius MA, Nightingale CH, Quintiliani R. Beneficial effect of adjunctive azithromycin in treatment of mucoid Pseudomonas aeruginosa pneumonia in the murine model. Antimicrob Agents Chemother. 1999 Dec; 43(12):3033-5. PMID: 10582906; PMCID: PMC89611.
    363. Nicolau DP, Tessier PR, Nightingale CH. Beneficial effect of combination antiplatelet therapy on the development of experimental Staphylococcus aureus endocarditis. Int J Antimicrob Agents. 1999 Feb; 11(2):159-61. PMID: 10221420.
      View in: PubMed
    364. Nicolau DP, Nie L, Tessier PR, Kourea HP, Nightingale CH. Prophylaxis of acute osteomyelitis with absorbable ofloxacin-impregnated beads. Antimicrob Agents Chemother. 1998 Apr; 42(4):840-2. PMID: 9559793; PMCID: PMC105552.
    Nicolau's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _